# Medical Research Analyst - Detailed Methods

**Version**: 1.0
**Last Updated**: 2025-12-07
**Status**: Active

æœ¬æ–‡æ¡£æä¾› Medical Research Analyst Skill çš„è¯¦ç»†æ–¹æ³•è®ºã€å®æ–½æ­¥éª¤å’Œæ•…éšœæ’é™¤æŒ‡å—ï¼Œæ˜¯ `skill_definition.md` ä¸­ Module 04 çš„æ‰©å±•ç‰ˆæœ¬ã€‚

---

## ğŸ“‹ Table of Contents

1. [Phase 1: Problem Definition](#phase-1-problem-definition)
2. [Phase 2: Literature Search](#phase-2-literature-search)
3. [Phase 3: Critical Appraisal](#phase-3-critical-appraisal)
4. [Phase 4: Synthesis & Analysis](#phase-4-synthesis--analysis)
5. [Phase 5: Structured Output](#phase-5-structured-output)
6. [Advanced Methods](#advanced-methods)
7. [Troubleshooting Guide](#troubleshooting-guide)
8. [Quality Assurance](#quality-assurance)

---

## Phase 1: Problem Definition

### Step 1.1: ä½¿ç”¨PICOæ¡†æ¶ç»“æ„åŒ–é—®é¢˜

**è¯¦ç»†æµç¨‹**ï¼š

#### 1.1.1 è¯†åˆ«æ ¸å¿ƒä¸´åºŠæƒ…å¢ƒ

**é—®é¢˜ç±»å‹åˆ†ç±»**ï¼š
- **Treatment/Intervention**: æ²»ç–—æ–¹æ¡ˆé€‰æ‹©ï¼ˆæœ€å¸¸è§ï¼‰
- **Prognosis**: é¢„åè¯„ä¼°
- **Diagnosis**: è¯Šæ–­ç­–ç•¥
- **Etiology/Harm**: ç—…å› æˆ–å±å®³å› ç´ 
- **Prevention**: é¢„é˜²æªæ–½

**ç¤ºä¾‹å¯¹è¯è„šæœ¬**ï¼š
```
Analyst: "è¯·æè¿°æ‚£è€…çš„åŸºæœ¬æƒ…å†µå’Œæ‚¨é¢ä¸´çš„ä¸»è¦å†³ç­–é—®é¢˜ã€‚"

User: "55å²å¥³æ€§ï¼ŒHER2+ä¹³è…ºç™Œï¼Œä¸€çº¿æ›²å¦¥ç å•æŠ—æ²»ç–—åè¿›å±•ï¼Œç°åœ¨æœ‰è„‘è½¬ç§»ï¼Œéœ€è¦é€‰æ‹©äºŒçº¿æ²»ç–—ã€‚"

Analystæ€è€ƒ:
â†’ Type: Treatmenté—®é¢˜
â†’ P: HER2+ mBC, post-trastuzumab, with brain mets
â†’ I: éœ€è¦è¯¢é—®è€ƒè™‘å“ªäº›æ²»ç–—é€‰é¡¹
â†’ C: éœ€è¦äº†è§£æ ‡å‡†å¯¹ç…§æ˜¯ä»€ä¹ˆ
â†’ O: ä¸»è¦å…³æ³¨ä»€ä¹ˆç»“å±€ï¼Ÿç–—æ•ˆè¿˜æ˜¯å®‰å…¨æ€§ï¼Ÿ
```

#### 1.1.2 å®Œæ•´PICOå®šä¹‰ï¼ˆé€é¡¹è¯¢é—®æ³•ï¼‰

**P (Population) - æ‚£è€…ç‰¹å¾æå–**ï¼š

**å¿…é—®æ¸…å•**ï¼š
- [ ] **ç–¾ç—…ç±»å‹**: å…·ä½“è¯Šæ–­ï¼ˆå¦‚HER2+ä¹³è…ºç™Œ vs æ³›æŒ‡ä¹³è…ºç™Œï¼‰
- [ ] **åˆ†æœŸ**: æ—©æœŸ vs æ™šæœŸ/è½¬ç§»æ€§
- [ ] **ç”Ÿç‰©æ ‡å¿—ç‰©**: HER2, ER/PR, EGFR, PD-L1ç­‰
- [ ] **æ—¢å¾€æ²»ç–—**: å‡ çº¿æ²»ç–—ï¼Ÿç”¨è¿‡ä»€ä¹ˆè¯ï¼Ÿ
- [ ] **ç‰¹æ®Šéƒ¨ä½è½¬ç§»**: è„‘è½¬ç§»ã€è‚è½¬ç§»ã€éª¨è½¬ç§»
- [ ] **æ‚£è€…ä¸€èˆ¬çŠ¶å†µ**: å¹´é¾„ã€PSè¯„åˆ†ã€å¹¶å‘ç—‡

**ç»“æ„åŒ–è®°å½•æ¨¡æ¿**ï¼š
```markdown
## Population Definition

**Core Diagnosis**: HER2-positive metastatic breast cancer

**Key Characteristics**:
- Stage: IV (metastatic)
- Biomarkers: HER2 3+ (IHC), ER+/PR+ (HR-positive)
- Prior Treatment: 1L trastuzumab + pertuzumab + taxane (progressed after 12 months)
- Metastatic Sites: Brain (3 lesions, largest 1.5cm), bone, liver
- Patient Factors: 55 years old, ECOG PS 1, no major comorbidities

**Inclusion Criteria** (for literature search):
- HER2+ metastatic breast cancer
- Post-trastuzumab exposure
- Brain metastases present (or subgroup data available)

**Exclusion Criteria**:
- HER2-negative disease
- Early-stage only
- No prior anti-HER2 therapy (de novo)
```

**I (Intervention) - å¹²é¢„æªæ–½æ˜ç¡®**ï¼š

**è¯¦ç»†è¦ç´ **ï¼š
- **Drug Name** (é€šç”¨å + å•†å“å)
- **Dose & Schedule** (å‰‚é‡å’Œç»™è¯æ–¹æ¡ˆ)
- **Route** (ç»™è¯é€”å¾„: IV, PO, SC)
- **Duration** (æ²»ç–—æŒç»­æ—¶é—´: å›ºå®šç–—ç¨‹ vs æŒç»­è‡³è¿›å±•)
- **Combination** (å•è¯ vs è”åˆæ²»ç–—)

**ç¤ºä¾‹**ï¼š
```markdown
## Intervention

**Primary Intervention**: Trastuzumab deruxtecan (T-DXd, EnhertuÂ®)
- Dose: 5.4 mg/kg
- Route: Intravenous infusion
- Schedule: Every 3 weeks (q3w)
- Duration: Until disease progression or unacceptable toxicity
- Combination: Monotherapy (no concurrent chemotherapy/endocrine therapy)
```

**C (Comparison) - å¯¹ç…§æªæ–½å®šä¹‰**ï¼š

**å¯¹ç…§ç±»å‹**ï¼š
1. **Active comparator**: å¦ä¸€ç§æ´»æ€§æ²»ç–—ï¼ˆå¦‚T-DM1ï¼‰
2. **Standard of care**: å½“å‰æ ‡å‡†æ²»ç–—
3. **Placebo + BSC**: å®‰æ…°å‰‚+æœ€ä½³æ”¯æŒæ²»ç–—
4. **Historical control**: å†å²å¯¹ç…§ï¼ˆå•è‡‚ç ”ç©¶ï¼‰
5. **No comparison**: å•çº¯æè¿°æ€§ç ”ç©¶

**ç¤ºä¾‹**ï¼š
```markdown
## Comparator

**Primary Comparator**: Ado-trastuzumab emtansine (T-DM1, KadcylaÂ®)
- Rationale: Current standard 2L treatment for HER2+ mBC
- Dose: 3.6 mg/kg IV q3w

**Alternative Comparators** (secondary analysis):
- Tucatinib + capecitabine + trastuzumab
- Lapatinib + capecitabine
- Physician's choice chemotherapy
```

**O (Outcomes) - ç»“å±€æŒ‡æ ‡åˆ†å±‚**ï¼š

**æŒ‰é‡è¦æ€§åˆ†çº§**ï¼š

| Priority | Outcome | Type | Rationale |
|----------|---------|------|-----------|
| **CRITICAL** | Progression-Free Survival (PFS) | Time-to-event | ä¸»è¦ç–—æ•ˆç»ˆç‚¹ |
| **CRITICAL** | Overall Survival (OS) | Time-to-event | æœ€ç»ˆè·ç›ŠæŒ‡æ ‡ |
| **CRITICAL** | CNS-PFS | Time-to-event | æ‚£è€…æœ‰è„‘è½¬ç§» |
| **IMPORTANT** | Objective Response Rate (ORR) | Binary | æ²»ç–—æœ‰æ•ˆæ€§ |
| **IMPORTANT** | Gradeâ‰¥3 Adverse Events | Safety | å®‰å…¨æ€§è¯„ä¼° |
| **IMPORTANT** | Quality of Life (QoL) | PRO | æ‚£è€…è§†è§’ |
| **OPTIONAL** | Duration of Response (DOR) | Time-to-event | ç¼“è§£æŒä¹…æ€§ |

**ç»“å±€å®šä¹‰æ ‡å‡†åŒ–**ï¼š
```markdown
## Outcome Definitions

**Primary Outcomes**:
1. **PFS** (Progression-Free Survival)
   - Definition: Time from randomization to disease progression (RECIST 1.1) or death
   - Assessment: BICR (Blinded Independent Central Review) preferred

2. **OS** (Overall Survival)
   - Definition: Time from randomization to death from any cause
   - Note: May not be mature in all studies

3. **CNS-PFS**
   - Definition: Time to progression in CNS or death
   - Assessment: Brain MRI every 6-9 weeks

**Secondary Outcomes**:
4. **ORR** (Objective Response Rate)
   - Definition: CR + PR per RECIST 1.1
   - Assessment: Best overall response

5. **Safety**
   - Definition: Incidence of Gradeâ‰¥3 AEs (CTCAE v5.0)
   - Special focus: ILD, hematologic toxicities

6. **QoL**
   - Instrument: EORTC QLQ-C30 / FACT-B
   - Minimally important difference: 10-point change
```

### Step 1.2: è¯†åˆ«å…³é”®å†³ç­–ç‚¹

**å†³ç­–æ ‘æ„å»º**ï¼š

```
[Primary Decision] é€‰æ‹©äºŒçº¿æ²»ç–—æ–¹æ¡ˆ
       |
       â”œâ”€ å†³ç­–ç‚¹1: ç–—æ•ˆä¼˜å…ˆ vs å®‰å…¨æ€§ä¼˜å…ˆï¼Ÿ
       |    â”œâ”€ ç–—æ•ˆä¼˜å…ˆ â†’ è€ƒè™‘T-DXdï¼ˆPFSæœ€ä¼˜ï¼‰
       |    â””â”€ å®‰å…¨æ€§ä¼˜å…ˆ â†’ è€ƒè™‘T-DM1æˆ–å£æœæ–¹æ¡ˆ
       |
       â”œâ”€ å†³ç­–ç‚¹2: è„‘è½¬ç§»æ˜¯å¦æ˜¯ä¸»è¦å…³æ³¨ç‚¹ï¼Ÿ
       |    â”œâ”€ Yes â†’ T-DXdæˆ–Tucatinibï¼ˆCNSç©¿é€æ€§å¥½ï¼‰
       |    â””â”€ No â†’ æ‰€æœ‰é€‰é¡¹å‡å¯è€ƒè™‘
       |
       â”œâ”€ å†³ç­–ç‚¹3: æ‚£è€…èƒ½å¦è€å—é™è„‰æ²»ç–—ï¼Ÿ
       |    â”œâ”€ Yes â†’ T-DXd/T-DM1å‡å¯
       |    â””â”€ No â†’ å£æœæ–¹æ¡ˆï¼ˆTucatinib+Cap+Tï¼‰
       |
       â””â”€ å†³ç­–ç‚¹4: ç»æµå¯åŠæ€§ï¼Ÿ
            â”œâ”€ å¯è´Ÿæ‹… â†’ é¦–é€‰æœ€ä¼˜ç–—æ•ˆæ–¹æ¡ˆ
            â””â”€ è´Ÿæ‹…é‡ â†’ è€ƒè™‘ä¸´åºŠè¯•éªŒæˆ–æ›¿ä»£æ–¹æ¡ˆ
```

**å†³ç­–æƒé‡çŸ©é˜µ**ï¼š

| å†³ç­–å› ç´  | æœ¬æ¡ˆä¾‹æƒé‡ | ç†ç”± |
|---------|----------|------|
| ç–—æ•ˆï¼ˆPFS/OSï¼‰ | 40% | æ‚£è€…å¹´è½»ã€PSå¥½ï¼Œè¿½æ±‚ç”Ÿå­˜è·ç›Š |
| CNSç–—æ•ˆ | 30% | æœ‰è„‘è½¬ç§»ï¼ŒCNSæ§åˆ¶æ˜¯å…³é”® |
| å®‰å…¨æ€§ | 20% | éœ€è¦å¹³è¡¡ï¼Œä½†ä¸æ˜¯é¦–è¦è€ƒè™‘ |
| ç”Ÿæ´»è´¨é‡ | 5% | æ¬¡è¦è€ƒè™‘ |
| ç»æµæ€§ | 5% | æ‚£è€…å¯è´Ÿæ‹… |

---

## Phase 2: Literature Search

### Step 2.1: æ„å»ºæ£€ç´¢ç­–ç•¥

#### 2.1.1 ç¡®å®šæ ¸å¿ƒæ£€ç´¢è¯

**æŒ‰PICOè¦ç´ åˆ†è§£**ï¼š

**P - Population Keywords**:
- MeSH Terms: `"Breast Neoplasms"[Mesh]`, `"Receptor, ErbB-2"[Mesh]`
- Text Words: `breast cancer`, `HER2-positive`, `HER2+`, `ERBB2`
- Modifiers: `metastatic`, `advanced`, `stage IV`

**I - Intervention Keywords**:
- MeSH Terms: `"Immunoconjugates"[Mesh]` (T-DXdæ˜¯æŠ—ä½“å¶è”è¯ç‰©)
- Text Words: `trastuzumab deruxtecan`, `T-DXd`, `DS-8201`, `Enhertu`

**C - Comparator Keywords** (å¯é€‰ï¼Œhead-to-headæ¯”è¾ƒæ—¶ä½¿ç”¨):
- `ado-trastuzumab emtansine`, `T-DM1`, `Kadcyla`

**O - Outcome Keywords** (å¯é€‰ï¼Œç²¾ç¡®æ£€ç´¢æ—¶ä½¿ç”¨):
- `progression-free survival`, `PFS`, `overall survival`, `OS`

**Study Design Keywords** (å¯é€‰ï¼Œé™å®šç ”ç©¶ç±»å‹):
- MeSH: `"Randomized Controlled Trial"[Publication Type]`
- Filters: `Clinical Trial`, `Meta-Analysis`, `Systematic Review`

#### 2.1.2 å¸ƒå°”é€»è¾‘ç»„åˆ

**åŸºæœ¬åŸåˆ™**ï¼š
- **AND**: è¿æ¥ä¸åŒæ¦‚å¿µï¼ˆP AND Iï¼‰
- **OR**: è¿æ¥åŒä¹‰è¯ï¼ˆbreast cancer OR breast carcinomaï¼‰
- **NOT**: æ’é™¤æ— å…³å†…å®¹ï¼ˆè°¨æ…ä½¿ç”¨ï¼Œå¯èƒ½é—æ¼ç›¸å…³ç ”ç©¶ï¼‰

**ä¼˜å…ˆçº§**: NOT > AND > OR

**æ‹¬å·ä½¿ç”¨**: æ˜ç¡®é€»è¾‘å…³ç³»

**å®Œæ•´æ£€ç´¢å¼ç¤ºä¾‹ï¼ˆPubMedï¼‰**ï¼š

```
#1  ("Breast Neoplasms"[Mesh] OR "breast cancer"[tiab] OR "breast carcinoma"[tiab])
#2  ("Receptor, ErbB-2"[Mesh] OR "HER2"[tiab] OR "HER2-positive"[tiab] OR "HER2 positive"[tiab] OR "ERBB2"[tiab])
#3  #1 AND #2                                     // HER2+ breast cancer

#4  ("trastuzumab deruxtecan"[tiab] OR "T-DXd"[tiab] OR "T DXd"[tiab] OR "DS-8201"[tiab] OR "DS 8201"[tiab] OR "Enhertu"[tiab])
#5  #3 AND #4                                     // HER2+ BC + T-DXd

#6  ("Neoplasm Metastasis"[Mesh] OR "metastatic"[tiab] OR "advanced"[tiab] OR "stage IV"[tiab])
#7  #5 AND #6                                     // HER2+ metastatic BC + T-DXd

#8  #7 AND ("2018/01/01"[PDAT] : "2025/12/07"[PDAT])    // æ—¶é—´é™åˆ¶

#9  #8 AND (English[lang] OR Chinese[lang])      // è¯­è¨€é™åˆ¶

#10 #9 AND ("Clinical Trial"[ptyp] OR "Randomized Controlled Trial"[ptyp] OR "Meta-Analysis"[ptyp])
                                                  // ç ”ç©¶ç±»å‹é™åˆ¶

FINAL: #10
```

**æ£€ç´¢å¼ä¼˜åŒ–æŠ€å·§**ï¼š

1. **æˆªè¯ç¬¦ä½¿ç”¨**ï¼ˆPubMedä¸­ç”¨*ï¼‰:
   ```
   "metasta*"[tiab]  â†’ åŒ¹é… metastasis, metastatic, metastases, metastasize
   ```

2. **çŸ­è¯­æ£€ç´¢**ï¼ˆåŒå¼•å·ï¼‰:
   ```
   "breast cancer"[tiab]  â†’ ç²¾ç¡®çŸ­è¯­
   breast cancer[tiab]    â†’ åˆ†å¼€åŒ¹é…ï¼ˆbreast AND cancerï¼‰
   ```

3. **å­—æ®µé™åˆ¶**:
   ```
   [tiab] = Title/Abstract
   [Mesh] = MeSH Terms
   [au] = Author
   [PDAT] = Publication Date
   ```

4. **é‚»è¿‘è¿ç®—ç¬¦**ï¼ˆPubMedä¸ç›´æ¥æ”¯æŒï¼Œéœ€ç”¨çŸ­è¯­ï¼‰:
   ```
   Embase: 'breast cancer' NEAR/5 'trastuzumab'  (5ä¸ªè¯ä»¥å†…)
   ```

#### 2.1.3 æ•°æ®åº“ç‰¹å®šè¯­æ³•

**Embase Syntax**:
```
#1  'breast cancer'/exp OR 'breast cancer':ab,ti
#2  'erb b2 receptor'/exp OR 'her2':ab,ti
#3  #1 AND #2
#4  'trastuzumab deruxtecan':ab,ti,tn OR 't dxd':ab,ti OR 'ds 8201':ab,ti
#5  #3 AND #4
#6  'metastasis'/exp OR 'metastatic':ab,ti
#7  #5 AND #6
#8  #7 AND [2018-2025]/py
#9  #8 AND ([english]/lim OR [chinese]/lim)

:ab,ti = Abstract/Title
:tn = Trade Name (å•†å“å)
/exp = explode (åŒ…å«ä¸‹ä½è¯)
/py = publication year
[randomized controlled trial]/lim = limit to RCTs
```

**Cochrane Library Syntax**:
```
#1  MeSH descriptor: [Breast Neoplasms] explode all trees
#2  (breast cancer OR breast carcinoma):ti,ab,kw
#3  #1 OR #2
#4  MeSH descriptor: [Receptor, ErbB-2] explode all trees
#5  (HER2 OR HER2-positive):ti,ab,kw
#6  #4 OR #5
#7  #3 AND #6
#8  (trastuzumab deruxtecan OR T-DXd OR DS-8201):ti,ab,kw
#9  #7 AND #8
#10 #9 with Cochrane Library publication date Between 2018 and 2025

:ti,ab,kw = Title/Abstract/Keywords
MeSH descriptor with "explode all trees" = åŒ…å«æ‰€æœ‰ä¸‹ä½MeSHè¯
```

### Step 2.2: æ‰§è¡Œå¤šæ•°æ®åº“æ£€ç´¢

**æ£€ç´¢é¡ºåºå»ºè®®**ï¼š
1. PubMedï¼ˆæœ€comprehensiveï¼Œå…è´¹ï¼‰
2. Cochrane Libraryï¼ˆé«˜è´¨é‡ç³»ç»Ÿç»¼è¿°ï¼‰
3. Embaseï¼ˆæ›´å…¨é¢ï¼ŒåŒ…å«ä¼šè®®æ‘˜è¦ï¼Œä½†éœ€è®¢é˜…ï¼‰
4. ClinicalTrials.govï¼ˆä¸´åºŠè¯•éªŒæ³¨å†Œä¿¡æ¯ï¼‰
5. ä¼šè®®æ•°æ®åº“ï¼ˆASCO, ESMO, AACRï¼‰

**è®°å½•è¦ç‚¹**ï¼š

| Database | Search Date | Strategy | Results | Notes |
|----------|-------------|----------|---------|-------|
| PubMed | 2025-12-07 | è§ä¸Š#10 | 156 | åŒ…å«RCTå’ŒMeta-analysis |
| Embase | 2025-12-07 | è§ä¸Š#9 | 234 | ä¸PubMedé‡å¤çº¦65% |
| Cochrane | 2025-12-07 | è§ä¸Š#10 | 12 | ç³»ç»Ÿç»¼è¿°ä¸ºä¸» |
| ClinicalTrials.gov | 2025-12-07 | Advanced search | 23 | åŒ…å«è¿›è¡Œä¸­è¯•éªŒ |

**å»é‡ç­–ç•¥**ï¼š
1. **è‡ªåŠ¨å»é‡**ï¼ˆEndNote, Zoteroç­‰æ–‡çŒ®ç®¡ç†è½¯ä»¶ï¼‰
2. **æ‰‹å·¥å»é‡**ï¼ˆæ£€æŸ¥DOI, PMID, NCTå·ï¼‰
3. **è¯†åˆ«é‡å¤å‘è¡¨**ï¼ˆåŒä¸€ç ”ç©¶çš„ä¸åŒæ—¶é—´ç‚¹æ›´æ–° â†’ ä¿ç•™æœ€æ–°æœ€å®Œæ•´ç‰ˆï¼‰

### Step 2.3: è¡¥å……æ£€ç´¢æ–¹æ³•

#### 2.3.1 Citation Tracking (å¼•æ–‡è¿½è¸ª)

**Forward Citation (è¢«å¼•ç”¨)**ï¼š
```
å·¥å…·: Google Scholar, Web of Science, Scopus

æ­¥éª¤:
1. è¯†åˆ«å…³é”®ç ”ç©¶ï¼ˆå¦‚DESTINY-Breast01, Modi et al. 2020ï¼‰
2. ç‚¹å‡»"Cited by"æŸ¥çœ‹æ‰€æœ‰å¼•ç”¨è¯¥ç ”ç©¶çš„æ–‡çŒ®
3. ç­›é€‰ç›¸å…³æ›´æ–°ã€è¯„è®ºã€Meta-analysis

ç¤ºä¾‹: DESTINY-Breast01è¢«å¼•524æ¬¡
    â†’ ç­›é€‰æ ‡é¢˜åŒ…å«"T-DXd"æˆ–"brain metastasis"çš„å¼•ç”¨
    â†’ å‘ç°3ç¯‡æ–°çš„çœŸå®ä¸–ç•Œç ”ç©¶å’Œ1ç¯‡Meta-analysis
```

**Backward Citation (å‚è€ƒæ–‡çŒ®)**ï¼š
```
æ­¥éª¤:
1. é˜…è¯»å·²çº³å…¥ç ”ç©¶çš„å‚è€ƒæ–‡çŒ®åˆ—è¡¨
2. è¯†åˆ«å¯èƒ½é—æ¼çš„ç›¸å…³ç ”ç©¶
3. è·å–å…¨æ–‡å¹¶è¯„ä¼°çº³å…¥

ç¤ºä¾‹: DESTINY-Breast03çš„ReferencesåŒ…å«T-DM1çš„å…³é”®ç ”ç©¶
    â†’ å‘ç°EMILIAå’ŒTH3RESAè¯•éªŒï¼ˆT-DM1ç–—æ•ˆæ•°æ®ï¼‰
    â†’ è¡¥å……çº³å…¥ä½œä¸ºå¯¹ç…§æ•°æ®
```

#### 2.3.2 Hand Search (æ‰‹å·¥æ£€ç´¢)

**ç›®æ ‡æœŸåˆŠåˆ—è¡¨**ï¼ˆOncology high-impact journalsï¼‰ï¼š
- New England Journal of Medicine (NEJM)
- The Lancet / Lancet Oncology
- Journal of Clinical Oncology (JCO)
- Journal of the National Cancer Institute (JNCI)
- Annals of Oncology

**æ£€ç´¢ç­–ç•¥**ï¼š
```
1. è®¿é—®æœŸåˆŠå®˜ç½‘
2. æµè§ˆæœ€è¿‘2å¹´çš„Table of Contents
3. æœç´¢æœŸåˆŠå†…éƒ¨æ•°æ®åº“ï¼ˆå¦‚NEJM.orgæœç´¢åŠŸèƒ½ï¼‰
4. è¯†åˆ«å¯èƒ½æœªè¢«PubMedåŠæ—¶ç´¢å¼•çš„æœ€æ–°ç ”ç©¶

æ—¶é—´æŠ•å…¥: æ¯ä¸ªæœŸåˆŠçº¦15-20åˆ†é’Ÿ
æ”¶ç›Š: å¯èƒ½å‘ç°åˆšå‘è¡¨ã€å°šæœªè¢«æ•°æ®åº“ç´¢å¼•çš„å…³é”®ç ”ç©¶
```

#### 2.3.3 Grey Literature (ç°è‰²æ–‡çŒ®)

**æ¥æº**ï¼š
1. **Clinical Trial Registries**:
   - ClinicalTrials.gov
   - EU Clinical Trials Register
   - ICTRP (WHO)

2. **Conference Abstracts**:
   - ASCO Annual Meeting & ASCO-GU/Breast/etc
   - ESMO Congress
   - AACR Annual Meeting
   - San Antonio Breast Cancer Symposium (SABCS)

3. **Regulatory Documents**:
   - FDA Drug Approval Packages
   - EMA Assessment Reports

**æ£€ç´¢ç¤ºä¾‹ï¼ˆASCO Abstractsï¼‰**ï¼š
```
ç½‘ç«™: https://meetings.asco.org/abstracts-presentations/

æ£€ç´¢è¯: "trastuzumab deruxtecan" OR "T-DXd"
è¿‡æ»¤å™¨: Year (2024, 2025), Cancer Type (Breast)

ç»“æœ: 12 abstracts
  â†’ 6ä¸ªå·²æ­£å¼å‘è¡¨ï¼ˆæ’é™¤ï¼‰
  â†’ 4ä¸ªæ˜¯äºšç»„åˆ†æï¼ˆçº³å…¥ï¼‰
  â†’ 2ä¸ªæ˜¯ongoing trialsçš„interim resultsï¼ˆçº³å…¥ï¼Œæ ‡æ³¨æ•°æ®æœªæˆç†Ÿï¼‰
```

---

## Phase 3: Critical Appraisal

### Step 3.1: ç ”ç©¶è´¨é‡è¯„ä¼°

#### 3.1.1 RCTè´¨é‡è¯„ä¼° (RoB 2.0)

**Cochrane Risk of Bias Tool 2.0** (RoB 2.0)

**5ä¸ªè¯„ä¼°åŸŸ**ï¼š

**Domain 1: Randomization Process (éšæœºåŒ–è¿‡ç¨‹)**

è¯„ä¼°è¦ç‚¹ï¼š
- [ ] éšæœºåºåˆ—ç”Ÿæˆæ–¹æ³•æ˜¯å¦åˆé€‚ï¼Ÿï¼ˆå¦‚è®¡ç®—æœºç”Ÿæˆéšæœºæ•°ï¼‰
- [ ] åˆ†é…éšè—æ˜¯å¦å……åˆ†ï¼Ÿï¼ˆå¦‚ä¸­å¤®éšæœºåŒ–ã€å¯†å°ä¿¡å°ï¼‰
- [ ] åŸºçº¿ç‰¹å¾æ˜¯å¦å¹³è¡¡ï¼Ÿ

åˆ¤æ–­æ ‡å‡†ï¼š
```
Low risk:
- æ˜ç¡®æè¿°äº†éšæœºæ–¹æ³•ï¼ˆå¦‚"computer-generated random sequence"ï¼‰
- åˆ†é…éšè—å……åˆ†ï¼ˆå¦‚"centralized web-based system"ï¼‰
- åŸºçº¿ç‰¹å¾å¹³è¡¡ï¼ˆp>0.05 for all key variablesï¼‰

Some concerns:
- éšæœºæ–¹æ³•æœªè¯¦ç»†æè¿°ï¼Œä½†æ— æ˜æ˜¾åå€šè¯æ®
- åŸºçº¿éƒ¨åˆ†ç‰¹å¾ä¸å¹³è¡¡ï¼Œä½†å·²åœ¨åˆ†æä¸­è°ƒæ•´

High risk:
- æ— éšæœºåŒ–æˆ–ä¼ªéšæœºåŒ–ï¼ˆå¦‚æŒ‰å°±è¯Šæ—¥æœŸåˆ†ç»„ï¼‰
- åˆ†é…éšè—ä¸å……åˆ†ï¼ˆå¦‚å¼€æ”¾å¼éšæœºè¡¨ï¼‰
- åŸºçº¿ä¸¥é‡ä¸å¹³è¡¡ä¸”æœªè°ƒæ•´
```

**ç¤ºä¾‹è¯„ä¼°ï¼ˆDESTINY-Breast03ï¼‰**ï¼š
```
Randomization Process: Low risk
- Method: "Interactive web response system" (IWRS)
- Allocation concealment: Adequate (centralized)
- Baseline balance: Well balanced (Table 1, all p>0.1)

Judgment: Low risk of bias
```

**Domain 2: Deviations from Intended Interventions (åç¦»é¢„æœŸå¹²é¢„)**

è¯„ä¼°è¦ç‚¹ï¼š
- [ ] æ˜¯å¦æœ‰protocol deviationsï¼ˆæ–¹æ¡ˆåç¦»ï¼‰ï¼Ÿ
- [ ] åç¦»æ˜¯å¦å¹³è¡¡ï¼ˆä¸¤ç»„ç›¸ä¼¼ï¼‰ï¼Ÿ
- [ ] åˆ†ææ˜¯å¦é‡‡ç”¨ITTåŸåˆ™ï¼ˆintention-to-treatï¼‰ï¼Ÿ

åˆ¤æ–­æ ‡å‡†ï¼š
```
Low risk:
- æå°‘æ–¹æ¡ˆåç¦»ï¼ˆ<5%ï¼‰ï¼Œä¸”ä¸¤ç»„å¹³è¡¡
- é‡‡ç”¨ITTåˆ†æï¼ˆall randomized patients includedï¼‰
- æ— é‡å¤§äº¤å‰æ±¡æŸ“ï¼ˆcrossoverï¼‰

Some concerns:
- æœ‰æ–¹æ¡ˆåç¦»ä½†å·²è®°å½•å¹¶åˆ†æ
- é‡‡ç”¨modified ITTï¼ˆæ’é™¤å°‘æ•°æœªæ¥å—ä»»ä½•æ²»ç–—çš„æ‚£è€…ï¼‰

High risk:
- å¤§é‡æ–¹æ¡ˆåç¦»ï¼ˆ>15%ï¼‰
- åç¦»ä¸å¹³è¡¡ï¼ˆå¦‚ä¸€ç»„switch rateæ˜æ˜¾é«˜ï¼‰
- ä»…åˆ†æå®Œæˆæ²»ç–—çš„æ‚£è€…ï¼ˆper-protocol onlyï¼‰
```

**ç¤ºä¾‹è¯„ä¼°ï¼ˆDESTINY-Breast03ï¼‰**ï¼š
```
Deviations: Low risk
- Treatment discontinuation due to AE: 16% (T-DXd) vs 10% (T-DM1)
- Crossover: Not allowed
- Analysis: ITT (all 524 randomized patients included)

Judgment: Low risk of bias
```

**Domain 3: Missing Outcome Data (ç»“å±€æ•°æ®ç¼ºå¤±)**

è¯„ä¼°è¦ç‚¹ï¼š
- [ ] å¤±è®¿ç‡ï¼ˆloss to follow-upï¼‰æ˜¯å¦ä½ï¼Ÿï¼ˆé€šå¸¸<20%ï¼‰
- [ ] å¤±è®¿æ˜¯å¦å¹³è¡¡ï¼Ÿ
- [ ] æ˜¯å¦è¿›è¡Œäº†æ•æ„Ÿæ€§åˆ†æï¼ˆsensitivity analysisï¼‰ï¼Ÿ

åˆ¤æ–­æ ‡å‡†ï¼š
```
Low risk:
- å¤±è®¿ç‡<5%
- ä¸¤ç»„å¤±è®¿ç‡ç›¸ä¼¼ï¼ˆdifference <2%)
- å…³é”®ç»“å±€æ•°æ®å®Œæ•´ï¼ˆå¦‚OS: æ‰€æœ‰æ‚£è€…å‡æœ‰ç”Ÿå­˜çŠ¶æ€è®°å½•ï¼‰

Some concerns:
- å¤±è®¿ç‡5-20%
- è¿›è¡Œäº†é€‚å½“çš„missing dataå¤„ç†ï¼ˆå¦‚multiple imputationï¼‰

High risk:
- å¤±è®¿ç‡>20%
- å¤±è®¿ä¸å¹³è¡¡ï¼ˆdifference >5%ï¼‰
- æœªå¤„ç†missing data
```

**Domain 4: Measurement of the Outcome (ç»“å±€æµ‹é‡)**

è¯„ä¼°è¦ç‚¹ï¼š
- [ ] ç»“å±€æµ‹é‡æ–¹æ³•æ˜¯å¦åˆé€‚ï¼Ÿ
- [ ] æ˜¯å¦é‡‡ç”¨ç›²æ³•è¯„ä¼°ï¼ˆå°¤å…¶æ˜¯ä¸»è§‚ç»“å±€ï¼‰ï¼Ÿ
- [ ] è¯„ä¼°è€…æ˜¯å¦çŸ¥é“åˆ†ç»„ï¼ˆassessor blindingï¼‰ï¼Ÿ

åˆ¤æ–­æ ‡å‡†ï¼š
```
Low risk:
- å®¢è§‚ç»“å±€ï¼ˆOS, lab valuesï¼‰
- ä¸»è§‚ç»“å±€é‡‡ç”¨ç›²æ³•è¯„ä¼°ï¼ˆBICR - Blinded Independent Central Reviewï¼‰
- è¯„ä¼°æ–¹æ³•æ ‡å‡†åŒ–ï¼ˆå¦‚RECIST 1.1 for PFSï¼‰

Some concerns:
- ä¸»è§‚ç»“å±€ä½†è¯„ä¼°è€…ç›²æ³•ä¸æ˜ç¡®
- æœªé‡‡ç”¨BICRä½†æœ‰investigator assessment

High risk:
- ä¸»è§‚ç»“å±€æ— ç›²æ³•ï¼ˆå¦‚QoLè¯„ä¼°ï¼Œæ‚£è€…å’ŒåŒ»ç”Ÿéƒ½çŸ¥é“åˆ†ç»„ï¼‰
- è¯„ä¼°æ–¹æ³•ä¸æ ‡å‡†
```

**ç¤ºä¾‹è¯„ä¼°ï¼ˆDESTINY-Breast03ï¼‰**ï¼š
```
Measurement: Low risk
- PFS: BICR (Blinded Independent Central Review) using RECIST 1.1
- OS: Objective (death from any cause)
- ORR: BICR

Judgment: Low risk of bias
```

**Domain 5: Selection of the Reported Result (æŠ¥å‘Šç»“æœé€‰æ‹©)**

è¯„ä¼°è¦ç‚¹ï¼š
- [ ] æ˜¯å¦é¢„å…ˆæ³¨å†Œäº†ç ”ç©¶æ–¹æ¡ˆï¼ˆtrial registrationï¼‰ï¼Ÿ
- [ ] æŠ¥å‘Šçš„ç»“å±€æ˜¯å¦ä¸æ–¹æ¡ˆä¸€è‡´ï¼Ÿ
- [ ] æ˜¯å¦æœ‰é€‰æ‹©æ€§æŠ¥å‘Šï¼ˆselective reportingï¼‰çš„è¯æ®ï¼Ÿ

åˆ¤æ–­æ ‡å‡†ï¼š
```
Low risk:
- åœ¨ClinicalTrials.govç­‰æ³¨å†Œ
- æ‰€æœ‰é¢„å…ˆæŒ‡å®šçš„ç»“å±€å‡å·²æŠ¥å‘Š
- åˆ†æè®¡åˆ’ä¸æ–¹æ¡ˆä¸€è‡´

Some concerns:
- æ³¨å†Œä½†æ—¶é—´è¾ƒæ™šï¼ˆå¦‚é¦–ä¾‹å…¥ç»„åæ‰æ³¨å†Œï¼‰
- éƒ¨åˆ†æ¬¡è¦ç»“å±€æœªæŠ¥å‘Šä½†æœ‰åˆç†è§£é‡Š

High risk:
- æœªæ³¨å†Œ
- ä¸»è¦ç»“å±€ä¸æ–¹æ¡ˆä¸ä¸€è‡´
- æ˜æ˜¾é€‰æ‹©æ€§æŠ¥å‘Šï¼ˆå¦‚åªæŠ¥å‘Šé˜³æ€§äºšç»„ï¼‰
```

**Overall RoB Judgment**:
```
Low risk: æ‰€æœ‰åŸŸéƒ½æ˜¯Low risk
Some concerns: è‡³å°‘ä¸€ä¸ªåŸŸæ˜¯Some concernsï¼Œä½†æ— High risk
High risk: è‡³å°‘ä¸€ä¸ªåŸŸæ˜¯High risk
```

**å®Œæ•´è¯„ä¼°ç¤ºä¾‹ï¼ˆDESTINY-Breast03ï¼‰**ï¼š

| Domain | Judgment | Support |
|--------|----------|---------|
| D1: Randomization | Low risk | IWRS, centralized, baseline balanced |
| D2: Deviations | Low risk | ITT analysis, minimal crossover |
| D3: Missing data | Low risk | <3% loss to follow-up, balanced |
| D4: Measurement | Low risk | BICR for PFS/ORR, OS objective |
| D5: Selective reporting | Low risk | NCT03529110, all outcomes reported |
| **Overall** | **Low risk** | All domains low risk |

#### 3.1.2 å•è‡‚è¯•éªŒè´¨é‡è¯„ä¼°

**è¯„ä¼°æ¡†æ¶ï¼ˆadapted from MINORSï¼‰**ï¼š

| Criterion | Score | Evidence in Study |
|-----------|-------|-------------------|
| **1. Clearly stated aim** | 0/1/2 | ç ”ç©¶ç›®çš„æ˜¯å¦æ¸…æ™°æ˜ç¡®ï¼Ÿ |
| **2. Inclusion of consecutive patients** | 0/1/2 | æ˜¯å¦è¿ç»­çº³å…¥ç¬¦åˆæ¡ä»¶çš„æ‚£è€…ï¼Ÿ |
| **3. Prospective data collection** | 0/1/2 | æ˜¯å¦å‰ç»æ€§æ”¶é›†æ•°æ®ï¼Ÿ |
| **4. Endpoints appropriate to study aim** | 0/1/2 | ç»ˆç‚¹ä¸ç ”ç©¶ç›®çš„æ˜¯å¦åŒ¹é…ï¼Ÿ |
| **5. Unbiased assessment of endpoints** | 0/1/2 | ç»ˆç‚¹è¯„ä¼°æ˜¯å¦æ— åï¼ˆå¦‚BICRï¼‰ï¼Ÿ |
| **6. Appropriate follow-up duration** | 0/1/2 | éšè®¿æ—¶é—´æ˜¯å¦è¶³å¤Ÿé•¿ï¼Ÿ |
| **7. Loss to follow-up <5%** | 0/1/2 | å¤±è®¿ç‡æ˜¯å¦ä½ï¼Ÿ |
| **8. Sample size calculation** | 0/1/2 | æ˜¯å¦æœ‰æ ·æœ¬é‡è®¡ç®—ï¼Ÿ |

**è¯„åˆ†**ï¼š
- 2åˆ† = å……åˆ†æ»¡è¶³
- 1åˆ† = éƒ¨åˆ†æ»¡è¶³æˆ–ä¸æ¸…æ¥š
- 0åˆ† = ä¸æ»¡è¶³æˆ–ç¼ºå¤±ä¿¡æ¯

**æ€»åˆ†**: 0-16åˆ†
- **12-16åˆ†**: High quality
- **8-11åˆ†**: Moderate quality
- **0-7åˆ†**: Low quality

**ç¤ºä¾‹è¯„ä¼°ï¼ˆDESTINY-Breast01ï¼‰**ï¼š

| Criterion | Score | Evidence |
|-----------|-------|----------|
| Clearly stated aim | 2 | Primary: ORR; Secondary: PFS, OS, safety |
| Consecutive patients | 2 | Multi-center enrollment, consecutive |
| Prospective collection | 2 | Prospective Phase II trial |
| Appropriate endpoints | 2 | ORRåˆé€‚å•è‡‚è¯•éªŒä¸»è¦ç»ˆç‚¹ |
| Unbiased assessment | 2 | BICR for tumor response |
| Follow-up duration | 1 | Median 11.1mï¼ŒOSæ•°æ®ä¸å¤Ÿæˆç†Ÿ |
| Loss to follow-up | 2 | <2% |
| Sample size calculation | 2 | Yes, based on ORR 40% (H0) vs 60% (H1) |
| **Total** | **15/16** | **High quality** |

### Step 3.2: è¯æ®ç­‰çº§è¯„å®š

#### 3.2.1 GRADE Evidence Quality

**GRADEåˆ†çº§ç³»ç»Ÿ**ï¼ˆGrading of Recommendations Assessment, Development and Evaluationï¼‰

**èµ·å§‹ç­‰çº§**ï¼ˆæ ¹æ®ç ”ç©¶è®¾è®¡ï¼‰ï¼š

| Study Design | Initial Grade |
|--------------|---------------|
| RCT | âŠ•âŠ•âŠ•âŠ• HIGH |
| Observational studies | âŠ•âŠ•âŠâŠ LOW |
| Uncontrolled case series | âŠ•âŠâŠâŠ VERY LOW |

**é™çº§å› ç´ **ï¼ˆæ¯ä¸ªå› ç´ å¯é™1-2çº§ï¼‰ï¼š

1. **Risk of Bias (åå€šé£é™©)**
   - ä¸¥é‡é™åˆ¶ï¼ˆ-1ï¼‰: 1ä¸ªæˆ–å¤šä¸ªåŸŸå­˜åœ¨"Some concerns"
   - éå¸¸ä¸¥é‡é™åˆ¶ï¼ˆ-2ï¼‰: 1ä¸ªæˆ–å¤šä¸ªåŸŸä¸º"High risk"

2. **Inconsistency (ä¸ä¸€è‡´æ€§)**
   - ä¸¥é‡ä¸ä¸€è‡´ï¼ˆ-1ï¼‰: IÂ²ç»Ÿè®¡é‡50-75%ï¼Œæ•ˆåº”æ–¹å‘ä¸€è‡´ä½†å¤§å°å·®å¼‚å¤§
   - éå¸¸ä¸¥é‡ä¸ä¸€è‡´ï¼ˆ-2ï¼‰: IÂ²>75%æˆ–æ•ˆåº”æ–¹å‘ä¸ä¸€è‡´

3. **Indirectness (é—´æ¥æ€§)**
   - ä¸¥é‡é—´æ¥ï¼ˆ-1ï¼‰: PICOä¸ç ”ç©¶é—®é¢˜éƒ¨åˆ†ä¸åŒ¹é…ï¼ˆå¦‚ä¸åŒäººç¾¤æˆ–æ›¿ä»£ç»“å±€ï¼‰
   - éå¸¸ä¸¥é‡é—´æ¥ï¼ˆ-2ï¼‰: é‡å¤§å·®å¼‚ï¼ˆå¦‚åŠ¨ç‰©å®éªŒå¤–æ¨è‡³äººç±»ï¼‰

4. **Imprecision (ä¸ç²¾ç¡®æ€§)**
   - ä¸¥é‡ä¸ç²¾ç¡®ï¼ˆ-1ï¼‰: æ ·æœ¬é‡å°ï¼Œ95%CIå®½ï¼ˆè·¨è¶Šæ— æ•ˆçº¿æˆ–åŒ…å«ä¸´åºŠé‡è¦å·®å¼‚çš„ä¸¤ä¾§ï¼‰
   - éå¸¸ä¸¥é‡ä¸ç²¾ç¡®ï¼ˆ-2ï¼‰: æ ·æœ¬é‡æå°ï¼ˆN<100ï¼‰ï¼ŒCIæå®½

5. **Publication Bias (å‘è¡¨åå€š)**
   - å¯èƒ½å­˜åœ¨ï¼ˆ-1ï¼‰: æ¼æ–—å›¾ä¸å¯¹ç§°ï¼Œæˆ–ä»…æœ‰å°æ ·æœ¬é˜³æ€§ç ”ç©¶

**å‡çº§å› ç´ **ï¼ˆè§‚å¯Ÿæ€§ç ”ç©¶å¯å‡çº§ï¼‰ï¼š

1. **Large Effect (æ•ˆåº”é‡å¤§)**
   - å¤§æ•ˆåº”ï¼ˆ+1ï¼‰: RR>2 æˆ– RR<0.5ï¼ˆä¸”æ— æ··æ‚ï¼‰
   - éå¸¸å¤§æ•ˆåº”ï¼ˆ+2ï¼‰: RR>5 æˆ– RR<0.2

2. **Dose-Response Gradient (å‰‚é‡ååº”å…³ç³»)**
   - æ˜ç¡®å‰‚é‡ååº”ï¼ˆ+1ï¼‰

3. **All Plausible Confounding Would Reduce Effect (æ‰€æœ‰æ··æ‚å› ç´ éƒ½ä¼šé™ä½æ•ˆåº”)**
   - è§‚å¯Ÿåˆ°çš„æ•ˆåº”å¯èƒ½ä½ä¼°ï¼ˆ+1ï¼‰

**æœ€ç»ˆç­‰çº§**ï¼š

| Grade | Definition | Implication |
|-------|------------|-------------|
| âŠ•âŠ•âŠ•âŠ• HIGH | éå¸¸ç¡®ä¿¡çœŸå®æ•ˆåº”æ¥è¿‘ä¼°è®¡å€¼ | Strong recommendation |
| âŠ•âŠ•âŠ•âŠ MODERATE | ä¸­ç­‰ç¡®ä¿¡ï¼ŒçœŸå®æ•ˆåº”å¯èƒ½æ¥è¿‘ | Conditional recommendation |
| âŠ•âŠ•âŠâŠ LOW | æœ‰é™ç¡®ä¿¡ï¼ŒçœŸå®æ•ˆåº”å¯èƒ½å·®å¼‚è¾ƒå¤§ | Weak recommendation |
| âŠ•âŠâŠâŠ VERY LOW | å‡ ä¹ä¸ç¡®ä¿¡ï¼ŒçœŸå®æ•ˆåº”å¯èƒ½æ˜¾è‘—ä¸åŒ | No recommendation |

**ç¤ºä¾‹è¯„ä¼°ï¼ˆT-DXd vs T-DM1 for PFSï¼‰**ï¼š

```
Study: DESTINY-Breast03 RCT

Starting grade: âŠ•âŠ•âŠ•âŠ• HIGH (RCT)

Downgrading considerations:
1. Risk of Bias: No serious limitation (all domains low risk) â†’ 0
2. Inconsistency: N/A (only 1 RCT) â†’ 0
3. Indirectness: No serious indirectness (PICO matches) â†’ 0
4. Imprecision: No serious imprecision (N=524, narrow CI, HR 0.33 [0.26-0.43]) â†’ 0
5. Publication Bias: Unlikely (large RCT, registered, negative result would also be published) â†’ 0

Upgrading considerations:
- Large effect: HR 0.33 (very large effect) â†’ +1 (ä½†RCTå·²æ˜¯HIGHï¼Œä¸å†å‡çº§)

Final Grade: âŠ•âŠ•âŠ•âŠ• HIGH

Interpretation:
éå¸¸ç¡®ä¿¡T-DXdç›¸æ¯”T-DM1æ˜¾è‘—å»¶é•¿PFSï¼ŒçœŸå®æ•ˆåº”éå¸¸æ¥è¿‘HR 0.33 (0.26-0.43)
```

**ç¤ºä¾‹è¯„ä¼°2ï¼ˆT-DXdå•è‡‚è¯•éªŒ ORRï¼‰**ï¼š

```
Study: DESTINY-Breast01 (Single-arm Phase II)

Starting grade: âŠ•âŠ•âŠâŠ LOW (non-comparative observational)
(æ³¨ï¼šå•è‡‚è¯•éªŒè§†ä¸ºobservational evidence for absolute effect estimation)

Downgrading:
1. Risk of Bias: No serious (high-quality design, BICR) â†’ 0
2. Inconsistency: Consistent with DESTINY-Breast02/03 â†’ 0
3. Indirectness: Directly applicable to target population â†’ 0
4. Imprecision: Moderate precision (N=184, 95%CI 53-68% for ORR 60.9%) â†’ 0
5. Publication Bias: Unlikely â†’ 0

Upgrading:
- Large effect: ORR 60.9% (historical control ~20-30%, RR>2) â†’ +1

Final Grade: âŠ•âŠ•âŠ•âŠ MODERATE

Interpretation:
ä¸­ç­‰ç¡®ä¿¡T-DXdçš„ORRçº¦60%ï¼ŒçœŸå®æ•ˆåº”å¯èƒ½åœ¨50-70%èŒƒå›´
```

#### 3.2.2 Oxford CEBM Levels of Evidence

**Oxford Centre for Evidence-Based Medicine (CEBM) Levels**

**æ²»ç–—æ•ˆæœï¼ˆTreatment Benefitsï¼‰**ï¼š

| Level | Type of Evidence | Example |
|-------|------------------|---------|
| **Level 1** | Systematic review of RCTs | Cochrane review of T-DXd RCTs |
| **Level 2** | Individual RCT | DESTINY-Breast03 |
| **Level 3** | Non-randomized controlled cohort/follow-up study | Prospective cohort of T-DXd vs historical T-DM1 |
| **Level 4** | Case-series, case-control, or historically controlled studies | Retrospective case series of T-DXd |
| **Level 5** | Mechanism-based reasoning | Preclinical data on T-DXd mechanism |

**è¯Šæ–­å‡†ç¡®æ€§ï¼ˆDiagnostic Accuracyï¼‰**ï¼š

| Level | Type of Evidence |
|-------|------------------|
| **Level 1** | Systematic review of cross-sectional studies; CDR* with 1b studies |
| **Level 2** | Individual cross-sectional studies with consistently applied reference standard and blinding |
| **Level 3** | Non-consecutive studies, or studies without consistently applied reference standards |
| **Level 4** | Case-control studies, or poor or non-independent reference standard |
| **Level 5** | Mechanism-based reasoning |

*CDR = Clinical Decision Rule

**é¢„åï¼ˆPrognosisï¼‰**ï¼š

| Level | Type of Evidence |
|-------|------------------|
| **Level 1** | Systematic review of inception cohort studies; CDR validated in different populations |
| **Level 2** | Individual inception cohort study |
| **Level 3** | Cohort study or control arm of RCT |
| **Level 4** | Case-series or case-control studies, or poor quality prognostic cohort study |
| **Level 5** | Mechanism-based reasoning |

**ä½¿ç”¨åœºæ™¯**ï¼š
- Oxford CEBMæ›´ç®€å•ç›´è§‚ï¼Œé€‚åˆå¿«é€Ÿåˆ†çº§
- GRADEæ›´ç³»ç»Ÿå…¨é¢ï¼Œé€‚åˆæŒ‡å—åˆ¶å®šå’ŒMeta-analysis

**å»ºè®®**ï¼š
```
åˆæ­¥è¯„ä¼° â†’ ä½¿ç”¨Oxford Levelså¿«é€Ÿåˆ†ç±»
æ·±åº¦åˆ†æ/æŒ‡å—åˆ¶å®š â†’ ä½¿ç”¨GRADEè¯¦ç»†è¯„ä¼°
æŠ¥å‘Šä¸­ â†’ åŒæ—¶å‘ˆç°ä¸¤ç§åˆ†çº§ï¼Œä¾¿äºä¸åŒè¯»è€…ç†è§£
```

---

## Phase 4: Synthesis & Analysis

### Step 4.1: å®šæ€§ç»¼åˆï¼ˆNarrative Synthesisï¼‰

**é€‚ç”¨åœºæ™¯**ï¼š
- ç ”ç©¶å¼‚è´¨æ€§å¤ªå¤§ï¼Œæ— æ³•Meta-analysis
- ç ”ç©¶è®¾è®¡å¤šæ ·ï¼ˆRCT + å•è‡‚ + è§‚å¯Ÿæ€§ï¼‰
- ç»“å±€æŒ‡æ ‡ä¸ä¸€è‡´

**æ–¹æ³•æ¡†æ¶**ï¼š

#### 4.1.1 æŒ‰ç ”ç©¶è®¾è®¡åˆ†å±‚ç»¼åˆ

```markdown
## Evidence Synthesis

### High-Quality RCTs (Level 1)

**DESTINY-Breast03** (CortÃ©s 2022, N=524):
- Design: Phase III, open-label RCT
- Population: HER2+ mBC, 2L, post-T Â± pertuzumab
- Comparison: T-DXd 5.4mg/kg q3w vs T-DM1 3.6mg/kg q3w
- Results:
  * PFS: 28.8m vs 6.8m (HR 0.33, 95%CI 0.26-0.43, p<0.001)
  * OS: NR vs 34.2m (HR 0.64, 95%CI 0.47-0.87, p=0.0037)
  * ORR: 79.7% vs 34.2%
  * CNS-PFS (subgroup): HR 0.25 (95%CI 0.13-0.50)
- Safety: Gradeâ‰¥3 AE 45% vs 39%; ILD 13.6% (Gradeâ‰¥3: 2.7%)
- Quality: Low risk of bias (RoB 2.0)
- GRADE: âŠ•âŠ•âŠ•âŠ• HIGH

**Interpretation**:
é«˜è´¨é‡è¯æ®è¡¨æ˜ï¼ŒT-DXdåœ¨HER2+ä¹³è…ºç™ŒäºŒçº¿æ²»ç–—ä¸­æ˜¾è‘—ä¼˜äºT-DM1ï¼ŒPFSå’ŒOSå‡æœ‰æ˜¾è‘—è·ç›Šï¼Œå®‰å…¨æ€§å¯æ¥å—ã€‚CNSç–—æ•ˆå°¤å…¶çªå‡ºï¼ˆHR 0.25ï¼‰ã€‚

### Single-Arm Trials (Level 2)

**DESTINY-Breast01** (Modi 2020, N=184):
- Design: Phase II, single-arm
- Population: HER2+ mBC, heavily pretreated (median 6 prior therapies)
- Intervention: T-DXd 5.4mg/kg q3w
- Results:
  * ORR: 60.9% (95%CI 53.4-68.0)
  * mPFS: 16.4m (95%CI 12.7-NE)
  * mDOR: 14.8m
  * 12-month OS: 86.2%
- Safety: Gradeâ‰¥3 AE 57.1%; ILD 13.6% (Gradeâ‰¥3/4/5: 2.7%)
- Quality: 15/16 (MINORS score), high quality
- GRADE: âŠ•âŠ•âŠ•âŠ MODERATE (single-arm, no direct comparator)

**Interpretation**:
åœ¨é«˜åº¦é¢„æ²»ç–—äººç¾¤ä¸­ï¼ŒT-DXdæ˜¾ç¤ºå‡ºä¸´åºŠæœ‰æ„ä¹‰çš„ORRï¼ˆ60.9%ï¼‰å’ŒæŒä¹…ç¼“è§£ï¼ˆmDOR 14.8mï¼‰ï¼Œæç¤ºåœ¨æ™šçº¿æ²»ç–—ä¸­ä»æœ‰æ´»æ€§ã€‚ILDéœ€å…³æ³¨ä½†å‘ç”Ÿç‡å¯æ§ã€‚

**DESTINY-Breast02** (AndrÃ© 2022, N=608):
- Similar design, confirms DESTINY-Breast01 findings
- ORR: 61.4%, mPFS: 17.8m
- Consistencyå¼ºåŒ–äº†T-DXdç–—æ•ˆçš„å¯ä¿¡åº¦

### Real-World Evidence (Level 3-4)

**ç»¼åˆ3é¡¹å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶** (Total N~500):
- çœŸå®ä¸–ç•ŒORR: 55-65%ï¼ˆä¸RCTä¸€è‡´ï¼‰
- mPFS: 12-18mï¼ˆç•¥ä½äºRCTï¼Œå¯èƒ½å› æ›´å·®çš„baselineç‰¹å¾ï¼‰
- ILDå‘ç”Ÿç‡: 10-15%ï¼ˆä¸ä¸´åºŠè¯•éªŒä¸€è‡´ï¼‰
- ç»“è®º: Real-world outcomesä¸RCTä¸€è‡´ï¼Œå¤–éƒ¨æ•ˆåº¦å¥½
```

#### 4.1.2 æŒ‰ç»“å±€æŒ‡æ ‡åˆ†å±‚ç»¼åˆ

```markdown
## Outcome-Specific Synthesis

### Efficacy Outcomes

**Primary Efficacy: Progression-Free Survival**

| Study | Design | Comparator | mPFS (T-DXd) | mPFS (Comparator) | HR (95%CI) | GRADE |
|-------|--------|------------|--------------|-------------------|------------|-------|
| DESTINY-Breast03 | RCT | T-DM1 | 28.8m | 6.8m | 0.33 (0.26-0.43) | âŠ•âŠ•âŠ•âŠ• |
| DESTINY-Breast01 | Single-arm | Historical | 16.4m | ~4-6m* | - | âŠ•âŠ•âŠ•âŠ |
| DESTINY-Breast02 | Single-arm | Historical | 17.8m | ~4-6m* | - | âŠ•âŠ•âŠ•âŠ |
| Real-world studies | Observational | Historical/T-DM1 | 12-18m | 5-7m | 0.35-0.50** | âŠ•âŠ•âŠâŠ |

*Historical control from prior trials in similar population
**Adjusted HR from propensity score matching

**Synthesis**:
- ä¸€è‡´æ€§å¼ºï¼šæ‰€æœ‰ç ”ç©¶å‡æ˜¾ç¤ºT-DXdæ˜¾è‘—å»¶é•¿PFS
- æ•ˆåº”é‡å¤§ï¼šHRçº¦0.33-0.35ï¼ˆRCTè¯æ®ï¼‰
- RCT vs çœŸå®ä¸–ç•Œ: çœŸå®ä¸–ç•ŒPFSç•¥çŸ­ï¼ˆ12-18m vs 28.8mï¼‰ï¼Œå¯èƒ½å› æ‚£è€…é€‰æ‹©åå€šï¼Œä½†HRç›¸ä¼¼ï¼ˆ0.35-0.50ï¼‰
- ç»“è®º: âŠ•âŠ•âŠ•âŠ• HIGH certainty that T-DXd improves PFS vs T-DM1

**Overall Survival**

| Study | Design | mOS (T-DXd) | mOS (Comparator) | HR (95%CI) | Maturity | GRADE |
|-------|--------|-------------|------------------|------------|----------|-------|
| DESTINY-Breast03 | RCT | NR | 34.2m | 0.64 (0.47-0.87) | 44% events | âŠ•âŠ•âŠ•âŠ• |
| DESTINY-Breast01 | Single-arm | 29.1m | - | - | Mature | âŠ•âŠ•âŠ•âŠ |

**Synthesis**:
- DESTINY-Breast03: OSæ˜¾è‘—æ”¹å–„ï¼ˆHR 0.64, p=0.0037ï¼‰ï¼Œå°½ç®¡æ•°æ®å°šæœªå®Œå…¨æˆç†Ÿ
- ç»å¯¹è·ç›Š: +9.9ä¸ªæœˆï¼ˆä¸´åºŠæœ‰æ„ä¹‰ï¼Œ>3ä¸ªæœˆï¼‰
- ç»“è®º: âŠ•âŠ•âŠ•âŠ• HIGH certainty that T-DXd improves OS vs T-DM1

**CNS-Specific Efficacy**

| Study | Population | CNS-PFS HR | CNS ORR | GRADE |
|-------|------------|-----------|---------|-------|
| DESTINY-Breast03 (subgroup) | Baseline brain mets (N=~100) | 0.25 (0.13-0.50) | 45.5% vs 21.1% | âŠ•âŠ•âŠ•âŠ* |
| DESTINY-Breast01 (subgroup) | Baseline brain mets (N=24) | - | 58.3% | âŠ•âŠ•âŠâŠ** |

*Downgraded for indirectness (subgroup analysis)
**Downgraded for small sample size and indirectness

**Synthesis**:
- T-DXdæ˜¾ç¤ºå¼ºå¤§çš„CNSæ´»æ€§ï¼ˆCNS-PFS HR 0.25ï¼‰
- CNS ORR 45-58%ï¼Œé«˜äºå…¨èº«ORRï¼ˆè„‘è½¬ç§»é€šå¸¸éš¾æ²»ï¼‰
- ç»“è®º: âŠ•âŠ•âŠ•âŠ MODERATE certainty that T-DXd has superior CNS efficacy

### Safety Outcomes

**Gradeâ‰¥3 Adverse Events**

| Study | T-DXd | Comparator | Difference | Common Gradeâ‰¥3 AEs |
|-------|-------|------------|------------|-------------------|
| DESTINY-Breast03 | 45% | 39% (T-DM1) | +6% | ä¸­æ€§ç²’ç»†èƒå‡å°‘(13% vs 8%), æ¶å¿ƒ(8% vs 2%) |
| DESTINY-Breast01 | 57% | - | - | ä¸­æ€§ç²’ç»†èƒå‡å°‘(21%), è´«è¡€(9%), æ¶å¿ƒ(8%) |

**Synthesis**:
- Gradeâ‰¥3 AEç‡: 45-57%ï¼ˆä¸­ç­‰ï¼Œç•¥é«˜äºT-DM1ä½†å¯æ¥å—ï¼‰
- ä¸»è¦ä¸ºè¡€æ¶²å­¦æ¯’æ€§ï¼ˆå¯é€†ï¼Œå¯ç®¡ç†ï¼‰
- NNH (Number Needed to Harm): 16.7 (Gradeâ‰¥3 AE increase)

**Interstitial Lung Disease (ILD) - Key Safety Concern**

| Study | ILD (Any Grade) | ILD (Gradeâ‰¥3) | ILD (Grade 5) | Management |
|-------|----------------|---------------|---------------|------------|
| DESTINY-Breast03 | 13.6% | 2.7% | 0.4% | å¤§å¤šæ•°Grade 1-2, å¯é€šè¿‡dose delay/reductionç®¡ç† |
| DESTINY-Breast01 | 13.6% | 2.7% | 2.2% | æ—©æœŸè¯†åˆ«å’ŒåŠæ—¶å¹²é¢„æ˜¯å…³é”® |
| Pooled analysis | ~12-15% | ~2-3% | ~0.5-2% | - |

**Synthesis**:
- ILDæ˜¯T-DXdçš„ç‰¹å¾æ€§AEï¼Œå‘ç”Ÿç‡çº¦13-15%
- å¤§å¤šæ•°ä¸ºè½»åº¦ï¼ˆGrade 1-2ï¼‰ï¼Œå¯é€šè¿‡åœè¯æˆ–å‡é‡ç®¡ç†
- Gradeâ‰¥3: ~2-3%ï¼ˆå¯æ¥å—ï¼‰
- è‡´å‘½ILD (Grade 5): ç½•è§(0.4-2.2%)ï¼Œéœ€å¯†åˆ‡ç›‘æµ‹å’Œæ—©æœŸè¯†åˆ«
- ç¼“è§£æªæ–½: åŸºçº¿è‚ºCTï¼Œæ²»ç–—ä¸­å®šæœŸé—®è¯¢å‘¼å¸é“ç—‡çŠ¶ï¼Œæœ‰ç—‡çŠ¶ç«‹å³CTè¯„ä¼°

**Treatment Discontinuation Due to AEs**

| Study | T-DXd | Comparator | Most Common Causes |
|-------|-------|------------|-------------------|
| DESTINY-Breast03 | 15.2% | 6.9% (T-DM1) | ILD (4%), decreased LVEF (1%), pneumonitis (1%) |

**Synthesis**:
- T-DXdçš„æ²»ç–—ä¸­æ–­ç‡çº¦15%ï¼Œé«˜äºT-DM1 (7%)
- ä¸»è¦åŸå› : ILDï¼ˆ4%ï¼‰
- NNH: éœ€æ²»ç–—12ä½æ‚£è€…ï¼Œä¼šæœ‰1äººå› AEåœè¯
- å¤§å¤šæ•°æ‚£è€…èƒ½å®Œæˆæ²»ç–—ï¼Œdiscontinuation rateå¯æ¥å—
```

### Step 4.2: å®šé‡ç»¼åˆï¼ˆMeta-Analysisï¼‰

**é€‚ç”¨åœºæ™¯**ï¼š
- â‰¥2ä¸ªç ”ç©¶æ¯”è¾ƒç›¸åŒå¹²é¢„
- ç»“å±€å®šä¹‰ä¸€è‡´
- ç ”ç©¶è®¾è®¡å¯æ¯”

**æ–¹æ³•**ï¼š

#### 4.2.1 æ•ˆåº”é‡æå–ä¸è½¬æ¢

**äºŒåˆ†ç±»ç»“å±€ï¼ˆå¦‚ORRï¼‰**ï¼š

æå–æ•°æ®ï¼š
- äº‹ä»¶æ•° (Events)
- æ€»æ ·æœ¬é‡ (Total)

è®¡ç®—æ•ˆåº”é‡ï¼š
- Risk Ratio (RR) = [Events_Intervention / Total_Intervention] / [Events_Control / Total_Control]
- Odds Ratio (OR) = [Events_I / (Total_I - Events_I)] / [Events_C / (Total_C - Events_C)]

ç¤ºä¾‹ï¼ˆDESTINY-Breast03ï¼‰ï¼š
```
T-DXd arm: ORR = 208/261 = 79.7%
T-DM1 arm: ORR = 90/263 = 34.2%

RR = 0.797 / 0.342 = 2.33 (95%CI: 1.95-2.79)
OR = (208/53) / (90/173) = 3.93 / 0.52 = 7.56
```

**æ—¶é—´-äº‹ä»¶ç»“å±€ï¼ˆå¦‚PFS, OSï¼‰**ï¼š

æå–æ•°æ®ï¼š
- Hazard Ratio (HR)
- 95% Confidence Interval
- (å¦‚æœæœªæŠ¥å‘ŠHRï¼Œä»Kaplan-Meieræ›²çº¿ä¼°ç®—æˆ–ä½¿ç”¨median PFS)

HRè§£é‡Šï¼š
- HR < 1: Interventioné™ä½é£é™©ï¼ˆæœ‰åˆ©ï¼‰
- HR = 1: æ— å·®å¼‚
- HR > 1: Interventionå¢åŠ é£é™©ï¼ˆä¸åˆ©ï¼‰

ç¤ºä¾‹ï¼š
```
DESTINY-Breast03: PFS HR = 0.33 (95%CI: 0.26-0.43)
è§£é‡Š: T-DXdä½¿è¿›å±•æˆ–æ­»äº¡é£é™©é™ä½67% (1-0.33=0.67)
```

#### 4.2.2 å¼‚è´¨æ€§è¯„ä¼°

**IÂ² Statistic (IÂ²ç»Ÿè®¡é‡)**ï¼š

å®šä¹‰: æ€»å˜å¼‚ä¸­ç”±å¼‚è´¨æ€§ï¼ˆè€ŒéæŠ½æ ·è¯¯å·®ï¼‰è§£é‡Šçš„æ¯”ä¾‹

å…¬å¼: IÂ² = [(Q - df) / Q] Ã— 100%
- Q = Cochran's Q statistic (å¼‚è´¨æ€§æ£€éªŒç»Ÿè®¡é‡)
- df = degrees of freedom (ç ”ç©¶æ•°-1)

è§£é‡Šï¼š
- IÂ² = 0-40%: å¯èƒ½ä¸é‡è¦ï¼ˆmight not be importantï¼‰
- IÂ² = 30-60%: å¯èƒ½ä»£è¡¨ä¸­ç­‰å¼‚è´¨æ€§ï¼ˆmay represent moderate heterogeneityï¼‰
- IÂ² = 50-90%: å¯èƒ½ä»£è¡¨substantialå¼‚è´¨æ€§
- IÂ² = 75-100%: ç›¸å½“å¤§çš„å¼‚è´¨æ€§ï¼ˆconsiderable heterogeneityï¼‰

**Ï„Â² (Tau-squared)**ï¼š
- ç ”ç©¶é—´æ–¹å·®çš„ä¼°è®¡å€¼
- ç”¨äºéšæœºæ•ˆåº”æ¨¡å‹

**Cochran's Q Test**ï¼š
- H0: æ‰€æœ‰ç ”ç©¶çš„çœŸå®æ•ˆåº”ç›¸åŒï¼ˆæ— å¼‚è´¨æ€§ï¼‰
- p < 0.10: æ‹’ç»H0ï¼Œå­˜åœ¨æ˜¾è‘—å¼‚è´¨æ€§

**å¤„ç†å¼‚è´¨æ€§çš„ç­–ç•¥**ï¼š

1. **ä½å¼‚è´¨æ€§ (IÂ² < 50%)**:
   - ä½¿ç”¨å›ºå®šæ•ˆåº”æ¨¡å‹ï¼ˆFixed-effect modelï¼‰
   - å‡è®¾æ‰€æœ‰ç ”ç©¶ä¼°è®¡åŒä¸€çœŸå®æ•ˆåº”

2. **ä¸­-é«˜å¼‚è´¨æ€§ (IÂ² â‰¥ 50%)**:
   - ä½¿ç”¨éšæœºæ•ˆåº”æ¨¡å‹ï¼ˆRandom-effects modelï¼‰
   - æ¢ç´¢å¼‚è´¨æ€§æ¥æºï¼ˆäºšç»„åˆ†æã€Meta-å›å½’ï¼‰
   - å¦‚æœIÂ² > 75%ä¸”æ— æ³•è§£é‡Šï¼Œè€ƒè™‘ä¸è¿›è¡ŒMeta-analysis

3. **æ¢ç´¢å¼‚è´¨æ€§æ¥æº**:
   - **äºšç»„åˆ†æ**: æŒ‰æ‚£è€…ç‰¹å¾ï¼ˆå¦‚è„‘è½¬ç§» vs æ— è„‘è½¬ç§»ï¼‰ã€æ²»ç–—çº¿æ•°ã€åœ°åŒºåˆ†å±‚
   - **Meta-å›å½’**: ç ”ç©¶è¿ç»­å˜é‡ï¼ˆå¦‚å¹³å‡å¹´é¾„ã€éšè®¿æ—¶é—´ï¼‰ä¸æ•ˆåº”é‡çš„å…³ç³»
   - **æ•æ„Ÿæ€§åˆ†æ**: æ’é™¤æŸäº›ç ”ç©¶åé‡æ–°åˆ†æ

ç¤ºä¾‹ï¼š
```
å‡è®¾æˆ‘ä»¬æœ‰3ä¸ªRCTæ¯”è¾ƒT-DXd vs Controlçš„PFS:

Study 1: HR 0.33 (0.26-0.43), Weight 45%
Study 2: HR 0.45 (0.30-0.68), Weight 30%
Study 3: HR 0.28 (0.18-0.44), Weight 25%

Meta-analysis:
Pooled HR = 0.35 (0.28-0.43)
IÂ² = 35% (low-moderate heterogeneity)
Q test p = 0.18 (not significant)

Interpretation:
- æ€»ä½“æ•ˆåº”: HR 0.35ï¼ŒT-DXdæ˜¾è‘—é™ä½è¿›å±•é£é™©65%
- å¼‚è´¨æ€§: ä½è‡³ä¸­ç­‰ï¼ˆIÂ²=35%ï¼‰ï¼Œç ”ç©¶ç»“æœç›¸å¯¹ä¸€è‡´
- ç»“è®º: å¯ä¿¡èµ–Meta-analysisç»“æœ
```

#### 4.2.3 å‘è¡¨åå€šè¯„ä¼°

**Funnel Plot (æ¼æ–—å›¾)**ï¼š

åŸç†:
- Xè½´: Effect size (å¦‚HR, OR)
- Yè½´: Precision (å¦‚Standard Error, 1/SE, sample size)
- æ— åå€šæ—¶: å°æ ·æœ¬ç ”ç©¶æ•£å¸ƒäºå¤§æ ·æœ¬ç ”ç©¶ä¸¤ä¾§ï¼Œå½¢æˆå¯¹ç§°æ¼æ–—
- æœ‰åå€šæ—¶: æ¼æ–—ä¸å¯¹ç§°ï¼ˆå¦‚ç¼ºå¤±å°æ ·æœ¬é˜´æ€§ç ”ç©¶ï¼‰

**Egger's Test (Eggeræ£€éªŒ)**ï¼š

ç»Ÿè®¡å­¦æ£€éªŒæ¼æ–—å›¾ä¸å¯¹ç§°æ€§
- H0: æ— å‘è¡¨åå€šï¼ˆæ¼æ–—å›¾å¯¹ç§°ï¼‰
- p < 0.05: æ‹’ç»H0ï¼Œå¯èƒ½å­˜åœ¨å‘è¡¨åå€š

**Trim-and-Fill Method**ï¼š

å‡è®¾ç¼ºå¤±ç ”ç©¶ï¼Œå¡«è¡¥åé‡æ–°è®¡ç®—pooled effect
- å¦‚æœå¡«è¡¥åæ•ˆåº”æ˜¾è‘—æ”¹å˜ â†’ å‘è¡¨åå€šå½±å“å¤§
- å¦‚æœå¡«è¡¥åæ•ˆåº”ç›¸ä¼¼ â†’ å‘è¡¨åå€šå½±å“å°

**æ³¨æ„äº‹é¡¹**ï¼š
- è‡³å°‘éœ€è¦10ä¸ªç ”ç©¶æ‰èƒ½å¯é è¯„ä¼°å‘è¡¨åå€š
- ä¸å¯¹ç§°ä¹Ÿå¯èƒ½ç”±å…¶ä»–åŸå› ï¼ˆçœŸå®å¼‚è´¨æ€§ã€ç ”ç©¶è´¨é‡å·®å¼‚ï¼‰å¯¼è‡´
- å¦‚æœä»…æœ‰å¤§å‹RCTï¼Œå‘è¡¨åå€šé€šå¸¸ä¸æ˜¯ä¸»è¦é—®é¢˜

---

## Phase 5: Structured Output

### Step 5.1: Executive Summaryæ’°å†™

**1-Minute ReadåŸåˆ™**ï¼š
- ç›®æ ‡: è¯»è€…ç”¨1åˆ†é’Ÿäº†è§£æ ¸å¿ƒç»“è®ºå’Œæ¨è
- é•¿åº¦: 150-200è¯ï¼Œæœ€å¤š3æ®µ
- å†…å®¹: é—®é¢˜+è¯æ®+æ¨è

**ç»“æ„æ¨¡æ¿**ï¼š

```markdown
# Executive Summary

**Clinical Question**: [1å¥è¯æè¿°PICO]

**Bottom Line**: [Strong/Conditional] recommendation for [Intervention] based on [è¯æ®è´¨é‡] evidence.

**Key Evidence**: [æœ€å…³é”®çš„RCTæˆ–Meta-analysisç»“æœ]
- Efficacy: [ä¸»è¦ç»ˆç‚¹æ•ˆåº”é‡]
- Safety: [ä¸»è¦å®‰å…¨æ€§é—®é¢˜]
- Evidence Quality: [GRADEç­‰çº§]

**Recommendation**:
- **First-line**: [æ¨èæ–¹æ¡ˆ]
- **Alternatives**: [å¤‡é€‰æ–¹æ¡ˆåŠé€‚ç”¨åœºæ™¯]
- **Monitoring**: [å…³é”®ç›‘æµ‹é¡¹]

**Confidence**: [High/Moderate/Low] - [ç®€è¿°ç†ç”±]
```

**ç¤ºä¾‹**ï¼š

```markdown
# Executive Summary

**Clinical Question**: å¯¹äºHER2é˜³æ€§è½¬ç§»æ€§ä¹³è…ºç™ŒäºŒçº¿æ²»ç–—ï¼ŒT-DXdç›¸æ¯”T-DM1æ˜¯å¦æ›´ä¼˜ï¼Ÿ

**Bottom Line**: **Strong recommendation** for T-DXd 5.4mg/kg IV q3w based on **high-quality evidence** from a large Phase III RCT.

**Key Evidence** (DESTINY-Breast03, N=524):
- **Efficacy**: T-DXdæ˜¾è‘—ä¼˜äºT-DM1
  - PFS: 28.8m vs 6.8m (HR 0.33, 95%CI 0.26-0.43, p<0.001) - ç»å¯¹è·ç›Š+22.0ä¸ªæœˆ
  - OS: NR vs 34.2m (HR 0.64, p=0.0037) - ç»å¯¹è·ç›Š+9.9ä¸ªæœˆ
  - ORR: 79.7% vs 34.2% (RR 2.33)
  - **CNS-PFS**: HR 0.25ï¼ˆè„‘è½¬ç§»æ‚£è€…å°¤å…¶è·ç›Šï¼‰

- **Safety**: å¯æ¥å—
  - Gradeâ‰¥3 AE: 45% vs 39% (NNH=16.7)
  - ILD: 13.6% (å¤§å¤šæ•°Grade 1-2ï¼Œå¯ç®¡ç†ï¼›Gradeâ‰¥3: 2.7%)
  - æ²»ç–—ä¸­æ–­ç‡: 15% vs 7% (ä¸»è¦å› ILD)

- **Evidence Quality**: âŠ•âŠ•âŠ•âŠ• HIGH (large RCT, low risk of bias)

**Recommendation**:
- **First-line choice**: T-DXd 5.4mg/kg IV q3wï¼Œç‰¹åˆ«é€‚åˆ:
  - æœ‰è„‘è½¬ç§»çš„æ‚£è€…ï¼ˆCNSç–—æ•ˆå“è¶Šï¼‰
  - å¹´è½»ã€ä½“èƒ½çŠ¶æ€å¥½ã€è¿½æ±‚æœ€å¤§ç–—æ•ˆçš„æ‚£è€…
  - æ— ILDé«˜å±å› ç´ çš„æ‚£è€…

- **Alternatives**:
  - Tucatinib+Cap+T: é€‚ç”¨äºILDé«˜é£é™©æˆ–åå¥½å£æœæ²»ç–—çš„æ‚£è€…
  - T-DM1: é€‚ç”¨äºè€å¹´å¤šå¹¶å‘ç—‡ã€ä¼˜å…ˆå®‰å…¨æ€§çš„æ‚£è€…

- **Key Monitoring**:
  - åŸºçº¿è‚ºCTï¼ˆæ’é™¤æ—¢å¾€ILDï¼‰
  - æ²»ç–—ä¸­æ¯æ¬¡å°±è¯Šè¯¢é—®å‘¼å¸é“ç—‡çŠ¶
  - æœ‰ç—‡çŠ¶ç«‹å³èƒ¸éƒ¨CTè¯„ä¼°

**Confidence**: **High** - åŸºäºå¤§å‹RCTï¼Œæ•ˆåº”é‡å¤§ï¼ˆHR 0.33ï¼‰ï¼Œç»“æœä¸€è‡´æ€§å¼ºï¼Œå·²çº³å…¥NCCN/ESMOä¸€ç±»æ¨èã€‚å®‰å…¨æ€§å¯æ§ï¼Œè·ç›Šè¿œè¶…é£é™©ã€‚
```

### Step 5.2: è¯¦ç»†æŠ¥å‘Šæ’°å†™

**å®Œæ•´æŠ¥å‘Šç»“æ„ï¼ˆIMRaD + GRADEï¼‰**ï¼š

```markdown
# [Report Title]
## Subtitle: Evidence-Based Analysis

**Date**: YYYY-MM-DD
**Analyst**: Medical Research Analyst Skill
**Evidence Level**: âŠ•âŠ•âŠ•âŠ• HIGH

---

## Table of Contents
1. Executive Summary
2. Background & Clinical Question
3. Methods
4. Results
   - 4.1 Literature Search
   - 4.2 Study Characteristics
   - 4.3 Efficacy Outcomes
   - 4.4 Safety Outcomes
   - 4.5 Quality of Evidence
5. Discussion
6. Recommendations
7. Implementation Guidance
8. Appendices

---

## 1. Executive Summary
[è§ä¸ŠèŠ‚]

---

## 2. Background & Clinical Question

### 2.1 Clinical Context
[ç®€è¿°ç–¾ç—…èƒŒæ™¯ã€å½“å‰æ²»ç–—ç°çŠ¶ã€æœªæ»¡è¶³çš„ä¸´åºŠéœ€æ±‚]

### 2.2 PICO Framework
[è¯¦ç»†PICOå®šä¹‰ï¼Œè§Phase 1]

### 2.3 Key Decision Points
[å†³ç­–æ ‘ï¼Œè§Phase 1]

---

## 3. Methods

### 3.1 Literature Search Strategy
**Databases**: PubMed, Embase, Cochrane Library, ClinicalTrials.gov
**Search Date**: 2025-12-07
**Search Terms**: [å®Œæ•´æ£€ç´¢å¼ï¼Œè§Phase 2]

### 3.2 Inclusion/Exclusion Criteria
[è¯¦ç»†çº³æ’æ ‡å‡†]

### 3.3 Study Selection
**PRISMA Flow**:
- Records identified: 443
- After deduplication: 85
- Full-text assessed: 85
- Studies included: 12 (3 RCTs, 6 single-arm, 3 observational)

### 3.4 Quality Assessment
- RCTs: Cochrane RoB 2.0
- Single-arm trials: MINORS
- Evidence grading: GRADE + Oxford CEBM

### 3.5 Data Extraction
- Efficacy: PFS, OS, ORR, CNS-PFS
- Safety: Gradeâ‰¥3 AE, ILD, treatment discontinuation
- Subgroup: Brain metastases, HR status, age

---

## 4. Results

### 4.1 Literature Search Results
[Evidence Summary Table - ä½¿ç”¨template]

### 4.2 Study Characteristics
[Baseline characteristics table]

### 4.3 Efficacy Outcomes

#### 4.3.1 Progression-Free Survival
[Forest plot if meta-analysis, or comparison table]

**DESTINY-Breast03**:
- mPFS: 28.8m (T-DXd) vs 6.8m (T-DM1)
- HR 0.33 (95%CI 0.26-0.43, p<0.001)
- 12m PFS rate: 75.8% vs 34.1%
- 24m PFS rate: 60.9% vs 14.4%

**Subgroup Analysis**:
[Forest plot of subgroups: brain mets, HR status, age, etc.]

**GRADE Assessment**: âŠ•âŠ•âŠ•âŠ• HIGH
- No serious limitations across all domains
- Large effect (HR 0.33)
- Consistent with single-arm trials

#### 4.3.2 Overall Survival
[Similar structure]

#### 4.3.3 Objective Response Rate
[Similar structure]

#### 4.3.4 CNS-Specific Outcomes
[Detailed CNS-PFS and CNS-ORR analysis]

### 4.4 Safety Outcomes

#### 4.4.1 Overall Adverse Events
[AE comparison table]

#### 4.4.2 Interstitial Lung Disease (ILD)
[Detailed ILD analysis: incidence, grading, management, risk factors]

#### 4.4.3 Treatment Discontinuation
[Reasons and rates]

### 4.5 Quality of Evidence

**GRADE Summary of Findings Table**:

| Outcome | Relative effect (95%CI) | Anticipated absolute effects | â„– of participants (studies) | Certainty | Comments |
|---------|------------------------|------------------------------|----------------------------|-----------|----------|
| PFS | HR 0.33 (0.26-0.43) | 28.8m vs 6.8m | 524 (1 RCT) | âŠ•âŠ•âŠ•âŠ• HIGH | Large effect, low RoB |
| OS | HR 0.64 (0.47-0.87) | NR vs 34.2m | 524 (1 RCT) | âŠ•âŠ•âŠ•âŠ• HIGH | Significant improvement |
| ORR | RR 2.33 (1.95-2.79) | 79.7% vs 34.2% | 524 (1 RCT) | âŠ•âŠ•âŠ•âŠ• HIGH | Clinically meaningful |
| CNS-PFS | HR 0.25 (0.13-0.50) | - | ~100 (subgroup) | âŠ•âŠ•âŠ•âŠ MODERATE | Indirect (subgroup) |
| Gradeâ‰¥3 AE | RR 1.15 (0.92-1.43) | 45% vs 39% | 524 (1 RCT) | âŠ•âŠ•âŠ•âŠ• HIGH | Acceptable |

---

## 5. Discussion

### 5.1 Summary of Key Findings
[Narrative synthesis]

### 5.2 Benefit-Risk Assessment
[NNT/NNH analysis, benefit-risk ratio]

### 5.3 Comparison with Guidelines
[NCCN, ESMO, ASCO recommendations]

### 5.4 Applicability to Target Population
[External validity, patient-specific considerations]

### 5.5 Limitations
- è¯æ®å±€é™ï¼ˆå¦‚OSæ•°æ®æœªæˆç†Ÿï¼‰
- ç ”ç©¶å±€é™ï¼ˆå¦‚ç¼ºå°‘æŸäº›äºšç»„æ•°æ®ï¼‰
- åˆ†æå±€é™ï¼ˆå¦‚æœªè¿›è¡Œnetwork meta-analysisï¼‰

### 5.6 Future Research Needs
[Knowledge gaps, ongoing trials]

---

## 6. Recommendations

### 6.1 Primary Recommendation
[è¯¦ç»†æ¨èï¼Œè§Decision Framework Template]

### 6.2 Alternative Recommendations
[åœºæ™¯ç‰¹å®šæ¨è]

### 6.3 Patient-Specific Considerations
[ä¸ªä½“åŒ–å†³ç­–æŒ‡å¯¼]

---

## 7. Implementation Guidance

### 7.1 Pre-Treatment Checklist
[è¯¦ç»†checklist]

### 7.2 Monitoring Plan
[è¯¦ç»†ç›‘æµ‹æ–¹æ¡ˆè¡¨æ ¼]

### 7.3 Dose Modification
[å‰‚é‡è°ƒæ•´æ–¹æ¡ˆ]

### 7.4 Toxicity Management
[ILDåŠå…¶ä»–AEçš„ç®¡ç†ç®—æ³•]

---

## 8. Appendices

### Appendix A: Full Search Strategies
[æ‰€æœ‰æ•°æ®åº“çš„å®Œæ•´æ£€ç´¢å¼]

### Appendix B: Excluded Studies
[æ’é™¤ç ”ç©¶åˆ—è¡¨åŠåŸå› ]

### Appendix C: Risk of Bias Assessments
[æ‰€æœ‰çº³å…¥RCTçš„è¯¦ç»†RoBè¯„ä¼°]

### Appendix D: GRADE Evidence Profiles
[è¯¦ç»†GRADEè¡¨æ ¼]

### Appendix E: Forest Plots
[Meta-analysisæ£®æ—å›¾ - å¦‚é€‚ç”¨]

### Appendix F: References
[å®Œæ•´å‚è€ƒæ–‡çŒ®åˆ—è¡¨]

---

**Document Information**:
- Version: 1.0
- Created: 2025-12-07
- Next Review: 2026-06-07 (æˆ–é‡å¤§æ–°è¯æ®å‘è¡¨æ—¶)
- Authors: Medical Research Analyst Skill, LiYe OS
- Evidence Quality: âŠ•âŠ•âŠ•âŠ• HIGH
- Recommendation Strength: Strong
```

---

## Advanced Methods

### Method 6.1: Network Meta-Analysis

**é€‚ç”¨åœºæ™¯**: å¤šä¸ªå¹²é¢„æªæ–½ï¼Œä½†ç¼ºå°‘ç›´æ¥å¤´å¯¹å¤´æ¯”è¾ƒ

**åŸç†**: é€šè¿‡å…±åŒå¯¹ç…§ï¼ˆå¦‚å®‰æ…°å‰‚æˆ–æ ‡å‡†æ²»ç–—ï¼‰é—´æ¥æ¯”è¾ƒä¸åŒå¹²é¢„

**ç¤ºä¾‹ç½‘ç»œ**:
```
       T-DXd
         |
         â†“
    [Standard Care] â† T-DM1
         â†‘
         |
    Tucatinib+Cap+T
```

**åˆ†ææ­¥éª¤**:
1. æ„å»ºè¯æ®ç½‘ç»œ
2. è¯„ä¼°ä¸€è‡´æ€§ï¼ˆConsistencyï¼‰: ç›´æ¥è¯æ® vs é—´æ¥è¯æ®æ˜¯å¦ä¸€è‡´
3. è¿›è¡ŒNetwork Meta-analysis
4. è®¡ç®—ç›¸å¯¹æ•ˆåº”ï¼ˆæ‰€æœ‰å¹²é¢„ä¸¤ä¸¤æ¯”è¾ƒï¼‰
5. æ’åºï¼ˆSUCRA - Surface Under the Cumulative Ranking curveï¼‰

**è½¯ä»¶**: R (netmeta package), Stata (network), WinBUGS

### Method 6.2: Bayesian Meta-Analysis

**ä¼˜åŠ¿**:
- å¯çº³å…¥å…ˆéªŒä¿¡æ¯
- æ›´é€‚åˆå°æ ·æœ¬ç ”ç©¶
- å¯è®¡ç®—åéªŒæ¦‚ç‡ï¼ˆå¦‚"T-DXdä¼˜äºT-DM1çš„æ¦‚ç‡æ˜¯95%"ï¼‰

**å·¥å…·**: WinBUGS, JAGS, Stan (via R)

### Method 6.3: Individual Patient Data (IPD) Meta-Analysis

**ä¼˜åŠ¿**:
- å¯è¿›è¡Œæ›´ç²¾ç¡®çš„äºšç»„åˆ†æ
- å¯ä½¿ç”¨time-to-eventæ•°æ®è¿›è¡Œæ›´å‡†ç¡®çš„åˆ†æ
- å¯è°ƒæ•´æ‚£è€…æ°´å¹³çš„æ··æ‚å› ç´ 

**æŒ‘æˆ˜**:
- éœ€è¦è·å¾—åŸå§‹æ‚£è€…æ•°æ®ï¼ˆé€šå¸¸éœ€è¦ä¸ç ”ç©¶ä½œè€…/è¯å‚è”ç³»ï¼‰
- æ•°æ®æ•´åˆå¤æ‚

---

## Troubleshooting Guide

### é—®é¢˜1: æ£€ç´¢ç»“æœè¿‡å¤šï¼ˆ>1000ç¯‡ï¼‰

**åŸå› **: æ£€ç´¢å¼å¤ªå®½æ³›

**è§£å†³æ–¹æ¡ˆ**:
1. å¢åŠ PICOçš„ç‰¹å¼‚æ€§ï¼ˆå¦‚é™å®špopulationä¸º"metastatic" AND "HER2-positive"ï¼‰
2. æ·»åŠ study designè¿‡æ»¤å™¨ï¼ˆå¦‚ä»…RCTï¼‰
3. ç¼©çŸ­æ—¶é—´èŒƒå›´ï¼ˆå¦‚æœ€è¿‘5å¹´ï¼‰
4. æ·»åŠ outcomeå…³é”®è¯

**ç¤ºä¾‹**:
```
è¿‡äºå®½æ³›: "breast cancer" AND "treatment"  â†’ 50,000+ results
ä¼˜åŒ–å: ("HER2-positive"[tiab] AND "metastatic breast cancer"[tiab]) AND ("trastuzumab deruxtecan"[tiab]) AND ("Clinical Trial"[ptyp])  â†’ 156 results
```

### é—®é¢˜2: æ£€ç´¢ç»“æœè¿‡å°‘ï¼ˆ<5ç¯‡ï¼‰

**åŸå› **: æ£€ç´¢å¼å¤ªçª„ï¼Œå¯èƒ½é—æ¼ç›¸å…³ç ”ç©¶

**è§£å†³æ–¹æ¡ˆ**:
1. æ‰©å±•åŒä¹‰è¯ï¼ˆå¦‚T-DXdè¿˜æœ‰DS-8201, Enhertuç­‰åˆ«åï¼‰
2. å»æ‰éƒ¨åˆ†é™åˆ¶ï¼ˆå¦‚ä¸é™å®šstudy designï¼‰
3. æ‰©å¤§æ—¶é—´èŒƒå›´
4. ä½¿ç”¨æˆªè¯ç¬¦ï¼ˆå¦‚metasta* åŒ¹é… metastatic, metastasis, metastasesï¼‰
5. æ£€æŸ¥æ‹¼å†™å’ŒMeSH termæ˜¯å¦æ­£ç¡®

**æ£€æŸ¥æ¸…å•**:
- [ ] æ˜¯å¦ç©·å°½äº†å¹²é¢„æªæ–½çš„æ‰€æœ‰åç§°ï¼Ÿï¼ˆé€šç”¨åã€å•†å“åã€ä»£å·ï¼‰
- [ ] æ˜¯å¦ä½¿ç”¨äº†MeSH Termsï¼Ÿ
- [ ] æ˜¯å¦é™åˆ¶è¿‡å¤šï¼ˆå¦‚ä»…è‹±æ–‡+ä»…RCT+ä»…æœ€è¿‘1å¹´ï¼‰ï¼Ÿ

### é—®é¢˜3: æ— æ³•æ‰¾åˆ°å…³é”®ç ”ç©¶çš„å…¨æ–‡

**è§£å†³æ–¹æ¡ˆ**:
1. **æœºæ„å›¾ä¹¦é¦†**: é€šè¿‡å¤§å­¦æˆ–åŒ»é™¢å›¾ä¹¦é¦†è·å–
2. **Open Accessç‰ˆæœ¬**: æ£€æŸ¥PubMed Central, Europe PMC
3. **é¢„å°æœ¬**: æ£€æŸ¥medRxiv, bioRxiv
4. **ä½œè€…è”ç³»**: å‘é‚®ä»¶è¯·æ±‚PDFï¼ˆé€šå¸¸ä½œè€…æ„¿æ„åˆ†äº«ï¼‰
5. **ResearchGate / Academia.edu**: ç ”ç©¶è€…å¯èƒ½ä¸Šä¼ äº†å…¨æ–‡
6. **ä»˜è´¹ä¸‹è½½**: å¦‚ç¡®å®éœ€è¦ä¸”æ— å…¶ä»–é€”å¾„

**é‚®ä»¶æ¨¡æ¿** (è”ç³»ä½œè€…):
```
Subject: Request for full-text of your article on [topic]

Dear Dr. [Author Name],

I am conducting a systematic review on [topic] and came across your article
"[Full Title]" published in [Journal, Year]. Unfortunately, I do not have
institutional access to this journal.

Would you be willing to share a PDF of this article for research purposes?

Thank you for considering my request.

Best regards,
[Your Name]
```

### é—®é¢˜4: ç ”ç©¶å¼‚è´¨æ€§å¤ªå¤§ï¼Œæ— æ³•Meta-analysis

**åˆ¤æ–­æ ‡å‡†**: IÂ² > 75% ä¸”æ— æ³•è§£é‡Šæ¥æº

**è§£å†³æ–¹æ¡ˆ**:
1. **ä¸è¿›è¡ŒMeta-analysis**: æ”¹ç”¨narrative synthesis
2. **äºšç»„åˆ†æ**: æŒ‰æ‚£è€…ç‰¹å¾ã€æ²»ç–—çº¿æ•°ã€åœ°åŒºåˆ†å±‚ååˆ†åˆ«Meta-analysis
3. **Meta-å›å½’**: æ¢ç´¢è¿ç»­å˜é‡ï¼ˆå¦‚å¹´é¾„ã€éšè®¿æ—¶é—´ï¼‰å¯¹æ•ˆåº”çš„å½±å“
4. **ä»…Meta-åˆ†æé«˜è´¨é‡/å¯æ¯”ç ”ç©¶**: æ’é™¤æ˜æ˜¾outliers

**æŠ¥å‘Šæ–¹å¼**:
```markdown
ç”±äºçº³å…¥ç ”ç©¶åœ¨[æ‚£è€…ç¾¤ä½“/å¹²é¢„å‰‚é‡/ç»“å±€å®šä¹‰]æ–¹é¢å­˜åœ¨æ˜¾è‘—å¼‚è´¨æ€§ï¼ˆIÂ²=85%, p<0.01ï¼‰ï¼Œ
æˆ‘ä»¬æœªè¿›è¡ŒMeta-analysisï¼Œè€Œæ˜¯é‡‡ç”¨narrative synthesisåˆ†å±‚æ€»ç»“è¯æ®ã€‚

å„ç ”ç©¶ç‹¬ç«‹åˆ†æç»“æœå‡æ˜¾ç¤ºT-DXdä¼˜äºå¯¹ç…§ï¼ˆHRèŒƒå›´: 0.28-0.50ï¼‰ï¼Œ
å°½ç®¡æ•ˆåº”é‡å¤§å°æœ‰å·®å¼‚ï¼Œä½†æ–¹å‘ä¸€è‡´ã€‚
```

### é—®é¢˜5: è¯æ®è´¨é‡ä¸è¶³ï¼ˆä»…æœ‰ä½è´¨é‡è§‚å¯Ÿæ€§ç ”ç©¶ï¼‰

**åˆ¤æ–­**: GRADEè¯„çº§ä¸ºâŠ•âŠ•âŠâŠ LOW æˆ– âŠ•âŠâŠâŠ VERY LOW

**è§£å†³æ–¹æ¡ˆ**:
1. **æ˜ç¡®æ ‡æ³¨è¯æ®é™åˆ¶**:
   ```markdown
   **Evidence Quality**: âŠ•âŠ•âŠâŠ LOW

   **Limitations**:
   - æ— RCTè¯æ®ï¼Œä»…æœ‰å›é¡¾æ€§é˜Ÿåˆ—ç ”ç©¶
   - é€‰æ‹©åå€šé£é™©é«˜ï¼ˆsick patients more likely to receive interventionï¼‰
   - æ··æ‚å› ç´ æœªå……åˆ†æ§åˆ¶

   **Implication**:
   - å»ºè®®è°¨æ…è§£è¯»ï¼ŒçœŸå®æ•ˆåº”å¯èƒ½ä¸è§‚å¯Ÿåˆ°çš„æ˜¾è‘—ä¸åŒ
   - å»ºè®®å¼€å±•å‰ç»æ€§RCTä»¥æä¾›é«˜è´¨é‡è¯æ®
   ```

2. **é™ä½æ¨èå¼ºåº¦**:
   - ä»"Strong Recommendation"é™ä¸º"Conditional Recommendation"
   - æˆ–"No recommendation due to insufficient evidence"

3. **å»ºè®®æ›¿ä»£æ–¹æ¡ˆ**:
   - å¦‚æœ‰å…¶ä»–è¯æ®è´¨é‡æ›´å¥½çš„æ²»ç–—é€‰æ‹©ï¼Œä¼˜å…ˆæ¨è

### é—®é¢˜6: å‘ç°ç ”ç©¶ç»“æœçŸ›ç›¾ï¼ˆæœ‰çš„é˜³æ€§ï¼Œæœ‰çš„é˜´æ€§ï¼‰

**ç¤ºä¾‹**: æŸä¸ªMeta-analysisæ˜¾ç¤ºT-DXdæœ‰æ•ˆï¼Œä½†å¦ä¸€ä¸ªRCTæ˜¾ç¤ºæ— æ•ˆ

**åˆ†ææ­¥éª¤**:
1. **æ£€æŸ¥PICOæ˜¯å¦ä¸€è‡´**:
   - æ‚£è€…ç¾¤ä½“æ˜¯å¦ç›¸åŒï¼Ÿï¼ˆå¦‚ä¸€çº¿ vs äºŒçº¿ï¼‰
   - å¹²é¢„å‰‚é‡æ˜¯å¦ä¸€è‡´ï¼Ÿ
   - ç»“å±€å®šä¹‰æ˜¯å¦ç›¸åŒï¼Ÿï¼ˆå¦‚PFSå®šä¹‰ï¼ŒRECIST 1.1 vs WHO criteriaï¼‰

2. **è¯„ä¼°ç ”ç©¶è´¨é‡**:
   - é˜´æ€§ç»“æœçš„ç ”ç©¶æ˜¯å¦æ ·æœ¬é‡ä¸è¶³ï¼ˆstatistical powerä½ï¼‰ï¼Ÿ
   - æ˜¯å¦æœ‰é«˜risk of biasï¼Ÿ

3. **æŸ¥çœ‹ç½®ä¿¡åŒºé—´**:
   - é˜³æ€§ç ”ç©¶: HR 0.33 (0.26-0.43) â†’ CIä¸è·¨1ï¼Œæ˜¾è‘—
   - é˜´æ€§ç ”ç©¶: HR 0.85 (0.50-1.45) â†’ CIè·¨1ï¼Œä¸æ˜¾è‘—ä½†ç‚¹ä¼°è®¡ä»æç¤ºè·ç›Š

4. **ç»¼åˆåˆ¤æ–­**:
   ```markdown
   ç ”ç©¶ç»“æœå­˜åœ¨ä¸ä¸€è‡´æ€§ï¼š
   - DESTINY-Breast03 (N=524, RCT): HR 0.33, æ˜¾è‘—
   - Study X (N=120, RCT): HR 0.85, ä¸æ˜¾è‘—

   å¯èƒ½åŸå› åˆ†æ:
   - Study Xæ ·æœ¬é‡å°ï¼ˆstatistical powerä¸è¶³ä»¥æ£€å‡ºå·®å¼‚ï¼‰
   - Study Xæ‚£è€…ç¾¤ä½“æ›´å·®ï¼ˆæ›´å¤šæ—¢å¾€æ²»ç–—çº¿æ•°ï¼ŒåŸºçº¿PSè¯„åˆ†æ›´ä½ï¼‰

   ç»¼åˆåˆ¤æ–­:
   - ä»¥å¤§æ ·æœ¬ã€é«˜è´¨é‡RCT (DESTINY-Breast03) ç»“æœä¸ºä¸»
   - Study Xçš„é˜´æ€§ç»“æœå¯èƒ½å› powerä¸è¶³å’Œæ‚£è€…é€‰æ‹©åå€š
   - æ€»ä½“è¯æ®æ”¯æŒT-DXdæœ‰æ•ˆï¼Œä½†ç‰¹å®šäººç¾¤ï¼ˆå¦‚æheavily pretreatedï¼‰è·ç›Šå¯èƒ½æœ‰é™
   ```

---

## Quality Assurance

### QA Checklistï¼ˆè´¨é‡ä¿è¯æ£€æŸ¥æ¸…å•ï¼‰

**Phase 1: Problem Definition**
- [ ] PICOæ˜¯å¦æ¸…æ™°æ˜ç¡®ï¼Œæ¯ä¸ªå…ƒç´ éƒ½å·²å®šä¹‰ï¼Ÿ
- [ ] å…³é”®å†³ç­–ç‚¹æ˜¯å¦è¯†åˆ«ï¼Ÿ
- [ ] ä¸ä¸´åºŠä¸“å®¶æˆ–ç”¨æˆ·ç¡®è®¤äº†ç ”ç©¶é—®é¢˜ï¼Ÿ

**Phase 2: Literature Search**
- [ ] è‡³å°‘æ£€ç´¢äº†3ä¸ªä¸»è¦æ•°æ®åº“ï¼Ÿ
- [ ] æ£€ç´¢å¼æ˜¯å¦è®°å½•å®Œæ•´ï¼ˆå¯é‡å¤ï¼‰ï¼Ÿ
- [ ] æ˜¯å¦ä½¿ç”¨äº†è¡¥å……æ£€ç´¢æ–¹æ³•ï¼ˆcitation tracking, hand searchï¼‰ï¼Ÿ
- [ ] æ£€ç´¢æ—¥æœŸæ˜¯å¦æ˜ç¡®æ ‡æ³¨ï¼Ÿ

**Phase 3: Critical Appraisal**
- [ ] æ‰€æœ‰çº³å…¥RCTéƒ½å®Œæˆäº†RoB 2.0è¯„ä¼°ï¼Ÿ
- [ ] è¯æ®ç­‰çº§è¯„å®šä½¿ç”¨äº†GRADEæˆ–Oxford CEBMï¼Ÿ
- [ ] è¯„ä¼°è¿‡ç¨‹æ˜¯å¦æœ‰è®°å½•ï¼ˆå¦‚RoBè¡¨æ ¼ï¼‰ï¼Ÿ

**Phase 4: Synthesis**
- [ ] è¯æ®ç»¼åˆæ˜¯å¦ç³»ç»ŸåŒ–ï¼ˆæŒ‰ç ”ç©¶è®¾è®¡æˆ–ç»“å±€åˆ†å±‚ï¼‰ï¼Ÿ
- [ ] å¦‚è¿›è¡ŒMeta-analysisï¼Œæ˜¯å¦è¯„ä¼°äº†å¼‚è´¨æ€§å’Œå‘è¡¨åå€šï¼Ÿ
- [ ] æ˜¯å¦è¿›è¡Œäº†æ•æ„Ÿæ€§åˆ†ææˆ–äºšç»„åˆ†æï¼Ÿ

**Phase 5: Output**
- [ ] Executive Summaryæ˜¯å¦ç®€æ´æ¸…æ™°ï¼ˆâ‰¤200è¯ï¼‰ï¼Ÿ
- [ ] æ¨èæ˜¯å¦æ˜ç¡®ï¼Œå¼ºåº¦å’Œè¯æ®è´¨é‡æ˜¯å¦æ ‡æ³¨ï¼Ÿ
- [ ] æ˜¯å¦æä¾›äº†implementation guidanceï¼Ÿ
- [ ] æ‰€æœ‰æ•°æ®æ˜¯å¦æœ‰referencesæ”¯æŒï¼Ÿ

**General**
- [ ] æ˜¯å¦æ— åˆ©ç›Šå†²çªï¼ˆconflict of interestï¼‰ï¼Ÿ
- [ ] æŠ¥å‘Šæ˜¯å¦å®¢è§‚ï¼Œé¿å…è¿‡åº¦è§£è¯»ï¼Ÿ
- [ ] æ˜¯å¦æ˜ç¡®æ ‡æ³¨äº†è¯æ®é™åˆ¶å’Œä¸ç¡®å®šæ€§ï¼Ÿ
- [ ] æ˜¯å¦è®¡åˆ’å®šæœŸæ›´æ–°ï¼ˆå¦‚6-12ä¸ªæœˆï¼‰ï¼Ÿ

### Peer Reviewï¼ˆåŒè¡Œè¯„å®¡ï¼‰

**å»ºè®®**: å¦‚æ¡ä»¶å…è®¸ï¼Œè¯·å¦ä¸€ä½åŒ»å­¦ç ”ç©¶åˆ†æå¸ˆæˆ–ä¸´åºŠåŒ»ç”Ÿå®¡é˜…æŠ¥å‘Š

**è¯„å®¡è¦ç‚¹**:
1. **ç§‘å­¦æ€§**: æ–¹æ³•æ˜¯å¦rigorousï¼Ÿç»“è®ºæ˜¯å¦æœ‰è¯æ®æ”¯æŒï¼Ÿ
2. **å®Œæ•´æ€§**: æ˜¯å¦é—æ¼äº†é‡è¦ç ”ç©¶æˆ–å…³é”®ä¿¡æ¯ï¼Ÿ
3. **å®¢è§‚æ€§**: æ˜¯å¦å­˜åœ¨åå€šæˆ–è¿‡åº¦è§£è¯»ï¼Ÿ
4. **å®ç”¨æ€§**: æ¨èæ˜¯å¦å¯æ“ä½œï¼Ÿæ˜¯å¦è€ƒè™‘äº†ä¸´åºŠå®é™…ï¼Ÿ

---

**Document Information**:
- **Version**: 1.0
- **Created**: 2025-12-07
- **Last Updated**: 2025-12-07
- **Maintained by**: Medical Research Analyst Skill, LiYe OS
- **Review Cycle**: æ¯6ä¸ªæœˆæˆ–æœ‰æ–°é‡å¤§è¯æ®æ—¶æ›´æ–°

---

*This methods document is a living resource and will be continuously improved based on practical experience and user feedback.*
